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To my family
”Den mätta dagen, den är aldrig störst.
Den bästa dagen är en dag av törst.
Nog finns det mål och mening i vår färd -
men det är vägen, som är mödan värd.
Det bästa målet är en nattlång rast,
där elden tänds och brödet bryts i hast.
På ställen, där man sover blott en gång,
blir sömnen trygg och drömmen full av sång.
Bryt upp, bryt upp! Den nya dagen gryr.
Oändligt är vårt stora äventyr.”
I rörelse. Karin Boye 1927 
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ABSTRACT
Background: Diabetes and previously undetected glucose abnormalities are common in patients with 
acute myocardial infarction (AMI). It is well established that patients with diabetes have a higher mortality 
rate after coronary events than patients without diabetes but the complication pattern in a contemporary 
perspective, the impact of glucose control and whether unknown glucose abnormalities affect the long-
term prognosis is less well studied. Data on the prognostic implications of adipokines in patients with 
prevalent coronary heart disease are contradictory and long-term outcome studies are lacking. 
Aims: To identify high-risk individuals and study long-term prognosis by
1. Investigating the lasting effect of intensified, insulin-based glucose control on mortality after AMI in  
patients with diabetes.
2. Analysing mortality and morbidity patterns after AMI in patients with newly discovered glucose  
abnormalities.
3. Investigating complication patterns after a first percutaneous coronary intervention. 
4. Analysing the significance of adiponectin and leptin as biomarkers of cardiovascular complications.
Glucose control and mortality after AMI: 306 patients with AMI and diabetes were randomised to 
intensified insulin-based glycaemic control while 314 served as controls in the DIGAMI-study. During 
a mean follow-up of 7.3 years 90% of the study population died. The median survival was 2.3 years 
longer in patients receiving intensified insulin-based glycaemic control after AMI (7.0 years) compared 
to patients in the control group (4.7 years).
Impact of undetected glucose abnormalities on long-term outcome after AMI: Patients (n=167) with 
AMI and healthy controls (n=184) without previously known diabetes (included in the GAMI study) 
were investigated with an oral glucose tolerance test (OGTT) at the time of hospital discharge (patients) 
or at inclusion (controls). Cardiovascular events (cardiovascular mortality, AMI, heart failure and stroke) 
during 10 years of follow-up were more frequent in patients with abnormal glucose tolerance than in 
patients with normal glucose tolerance and in controls. Abnormal glucose tolerance at the OGTT was 
independently associated with future cardiovascular events after an AMI (HR 2.30; 95% CI 1.24-4.25, 
p=0.008) in contrast to HbA1c (p=0.81) and fasting blood glucose (p=0.52). 
Long-term outcome after coronary artery disease and revascularisation: High event rates of 
mortality, heart failure, myocardial infarction and stroke were demonstrated after a first percutaneous 
coronary intervention in patients with diabetes followed up to five years after inclusion in the Swedish 
Coronary Angiography Angioplasty Registry (SCAAR) between 2006-2010 (n=58891, 19% with 
diabetes). Diabetes was an independent predictor for mortality and cardiovascular events. Insulin-treated 
patients were at a particularly high risk. 
Adiponectin and leptin as biomarkers for identifying high risk patients: In 180 patients with AMI 
and without diabetes (the GAMI cohort) elevated levels of adiponectin at discharge independently 
predicted mortality (HR 1.79; 95% CI 1.07-3.00, p=0.027) but not cardiovascular events the coming 
decade. High levels of leptin at day 2 were associated with cardiovascular events during the first seven 
years but did not predict mortality.
Conclusion: Diabetes and previously undetected glucose abnormalities are common in patients 
with coronary events and their presence has a negative influence on the prognosis. Despite improved 
longevity patients with diabetes are still at increased risk for mortality and cardiovascular complications. 
An OGTT, but not HbA1c, identifies patients with previously undetected glucose abnormalities at 
increased cardiovascular risk the next coming 10 years. These findings support that an OGTT should 
be considered as an important screening tool after AMI. High levels of adiponectin and leptin identifies 
patients with compromised outcome after AMI. Future studies are warranted to confirm their role as 
suitable biomarkers. Finally a close follow-up of patients with glucose abnormalities is advocated where 
multifactorial treatment is important to improve long-term survival after AMI. The present studies do 
also underline that new treatment strategies are highly warranted.  
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SAMMANFATTNING
Bakgrund: Diabetes och tidigare oupptäckt glukosstörning är vanligt hos patienter med akut hjärtinfarkt. 
Patienter med diabetes har högre dödlighet efter kranskärlshändelser men hur komplikationerna ser ut i 
ett modernt perspektiv efter en sådan händelse är mindre känt. Vidare är det oklart om glukoskontroll och 
okända glukosstörningar påverkar den långsiktiga prognosen. Uppgifter om adipokiners prognostiska 
roll hos patienter med akut hjärtinfarkt är motsägelsefulla och långtidsstudier saknas.
Mål: Att identifiera högriskindivider och studera den långsiktiga prognosen genom att
1. Utvärdera den varaktiga effekten av intensifierad insulinbaserad blodsockerkontroll efter akut 
hjärtinfarkt hos patienter med känd diabetes
2. Undersöka komplikationsmönster efter hjärtinfarkt hos patienter med nyupptäckta glukosstörningar
3. Studera komplikationsmönster efter ett första kateterburet kranskärlsingrepp 
4. Analysera betydelsen av biomarkörerna adiponektin och leptin för kardiovaskulära komplikationer 
efter en akut hjärtinfarkt
Glukoskontroll och dödlighet efter akut hjärtinfarkt: I DIGAMI-studien randomiserades 306 
patienter med akut hjärtinfarkt och diabetes till intensifierad insulinbaserad glukoskontroll och 314 
till konventionell behandling. Under en genomsnittlig uppföljningsperiod på 7.3 år avled 90% av 
studiepopulationen. Medianöverlevnaden ökade med 2.3 år hos patienter som erhöll intensifierad 
insulinbaserad glukoskontroll jämfört med patienterna i kontrollgruppen. 
Långsiktiga effekter av oupptäckta glukosstörningar vid akut hjärtinfarkt: I GAMI-studien 
undersöktes patienter (n=167) med akut hjärtinfarkt och friska kontroller (n=184) utan tidigare känd 
diabetes med glukosbelastning (OGTT) vid utskrivning (patienter) eller vid inklusion (kontroller). Under 
den 10 år långa uppföljningen var kardiovaskulära händelser (kardiovaskulär dödlighet, hjärtinfarkt, 
hjärtsvikt och stroke) vanligare hos patienter med nyupptäckt glukosstörning jämfört med patienter med 
normal glukostolerans och vanligare än i kontrollgruppen. Glukosstörning upptäckt med OGTT var en 
oberoende riskfaktor för framtida kardiovaskulära händelser efter akut hjärtinfarkt (HR 2.30, 95% CI 
1.24-4.25, p=0.008) till skillnad från HbA1c (p=0.81) och fasteblodsocker (p=0.52).
Långsiktig prognos efter kranskärlssjukdom och revaskularisering: En hög komplikationsfrekvens 
(dödlighet, hjärtsvikt, hjärtinfarkt och stroke) under fem års uppföljning sågs hos patienter med diabetes 
som genomgick ett första kateterburet kranskärlsingrepp och inkluderades i Svenska Koronarangiografi 
och Angioplastik Registret (SCAAR) mellan 2006-2010 (n=58891, 19% med diabetes). Diabetes var 
en oberoende riskfaktor för dödlighet och kardiovaskulära händelser där särskilt hög risk sågs hos 
insulinbehandlade patienter. 
Adiponektin och leptin som biomarkörer för att identifiera högriskpatienter: Förhöjda nivåer av 
adiponektin 4-5 dagar efter en hjärtinfarkt var en oberoende markör för dödlighet det följande decenniet 
(HR 1.79; 95% CI 1.07-3.00, p=0.027) men inte för kardiovaskulära händelser hos patienter utan tidigare 
känd diabetes (n=180; GAMI kohorten). Höga nivåer av leptin dag två var relaterat till kardiovaskulära 
händelser under de följande sju åren men var inte relaterat till dödlighet.  
Slutsats: Diabetes och tidigare oupptäckt glukosstörning är vanligt hos patienter med kranskärlssjukdom 
och påverkar prognosen negativt. Trots förbättrad livslängd har patienter med diabetes fortfarande en 
ökad risk för förtida dödlighet samt nya kardiovaskulära händelser. OGTT, men inte HbA1c, identifierar 
individer med tidigare oupptäckt glukosstörning och med samtidig ökad risk för kardiovaskulära händelser 
det kommande decenniet efter en hjärtinfarkt. OGTT bör därför övervägas utgöra ett screeningverktyg 
efter akut hjärtinfarkt. Höga nivåer av adiponektin och leptin identifierar patienter med sämre prognos 
efter akut hjärtinfarkt. Sammantaget bör patienter med glukosstörningar bli föremål för en noggrann 
uppföljning där multifaktoriell behandling och nya behandlingsstrategier är viktigt för att förbättra den 
långsiktiga överlevnaden och minska sjukligheten efter hjärtinfarkt. 
Viveca Ritsinger
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LIST OF ABBREVIATIONS
ACCORD Action to Control Cardiovascular Risk in Diabetes
ADA American Diabetes Association
ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation
AGT Abnormal glucose tolerance
AMI Acute myocardial infarction
CABG Coronary artery bypass grafting
CAD Coronary artery disease
CHD Coronary heart disease
CVD Cardiovascular disease
DCCT The Diabetes Control and Complications Trial
DIGAMI Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial 
Infarction 
EMPA-REG 
OUTCOME
(Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients
FFA Free fatty acids
GAMI Glucose Tolerance in Patients with Acute Myocardial Infarction
HOMA-IR Homeostasis model assessment of insulin resistance
IFG Impaired fasting glucose
IGI Insulinogenic index
IGT Impaired glucose tolerance
IKKβ IkappaB kinase-beta
IL-6 Interleukin-6
JNK Jun N-terminal kinase 
LEADER Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results
NFkB Nuclear factor kappa-light-chain-enhancer of activated B cells
NGT Normal glucose tolerance
OGTT Oral glucose tolerance test
PAI-1 Plasminogen activator inhibitor-1
PCI Percutaneous coronary intervention
ROS Reactive oxygen species
SCAAR Swedish Coronary Angiography and Angioplasty Registry
SUSTAIN-6 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With 
Semaglutide in Subjects With Type 2 Diabetes
TNF-α Tumor necrosis factor-alpha
UKPDS United Kingdom Prospective Diabetes Study
WHO World Health Organisation
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INTRODUCTION
Diabetes from an historical perspective
Diabetes has been known for thousands of years and a disease resembling diabetes was 
first described by the Egyptians 3000-1500 years before Christ. Aretaeus of Cappadocia 
referred to the disease as diabetes, a composite of the Greek words dia (across) and bainein 
(to straddle) meaning “the passage of large quantities of urine”. Mellitus (honey) was 
added by Thomas Willis as the glucose-rich urine tasted like honey. In 1776, the glucose 
concentration in urine was shown to be increased in patients with diabetes.1 However, until 
the beginning of the 19th century, the diagnosis of diabetes was mainly based on the taste of 
urine and as a result the diagnosis was fairly uncommon. In 1869, Paul Langerhans reported 
two cellular systems in the pancreas and several years later one of them was named the 
“islets of Langerhans” by Gustave-Édouard Laguesse. Twenty years later, in 1889, Joseph 
von Mering and Oskar Minkowski demonstrated that dogs in which the pancreas had been 
removed developed diabetes.2 At the end of the 19th century tools for measuring glucose 
in urine became available to the public. Accordingly, there was a rise in the diagnosis of 
diabetes but still without any possible treatment. In 1921, a dramatic change took place in the 
lives of patients with diabetes, as insulin was discovered by Frederick Banting and Charles 
Best and the first patient was treated in 1922 (Figure 1).3 Since then, the pathophysiology 
of diabetes has been further examined also enabling the development of other classes of 
glucose-lowering medication. In 1965, the first classification of diabetes was published by 
the WHO (classification by age). Since then, the WHO has continued to publish and detail 
the diagnostic criteria for diabetes in 1980,4 1985 (1980 and 1985 classification by insulin 
dependence was used),5 1999 (classification by aetiology starts),6 20067 and 2011.8
Figure 1. Banting and Best in the laboratory. Unknown artist.
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Terminology and aetiology of diabetes
Diabetes is a metabolic disease affecting the carbohydrate, lipid and protein metabolism 
characterised by chronic hyperglycaemia due to an absolute or relative insulin deficiency. 
Diabetes mellitus is currently classified in four main forms (Figure 2) where this thesis will 
focus on type 2 diabetes.
Impaired glucose regulation
In addition to diabetes, there are states with a higher blood glucose than normal  but still not 
reaching the defined cut-off points for diabetes. These conditions are labelled as impaired 
glucose regulation and include impaired glucose tolerance (IGT= elevated postprandial blood 
glucose detected by an oral glucose tolerance test [OGTT]) and impaired fasting glucose 
(IFG= elevated fasting glucose). It is thought that IFG and IGT probably represent different 
abnormalities in glucose regulation with IFG more related to impaired insulin secretion and 
IGT to decreased insulin sensitivity12 and the metabolic syndrome.13 Several reports describe 
a gender difference, where IFG is more common among men and IGT is more common in 
women.14-17 It is postulated that the gender differences are due to differences in lipid profile 
and other parts of the metabolic syndrome in men and women. Impaired glucose regulation 
is sometimes referred to as “prediabetes” as it is regarded as a condition with an increased 
risk of future diabetes. This is a process that takes years. The reported annual rate of type 2 
diabetes varies from 1-10% in people with IFG and from 2-11% in those with IGT, depending 
on a diverse risk profile in different study populations.17-20 For individuals with both IFG and 
IGT the risk is even higher. In a Swedish population, 14% of those with IFG and 17% of 
those with IGT developed diabetes after 10 years compared with 49% of those with both 
IFG and IGT.17 Several years of lifestyle modification and/or pharmaceutical treatment with 
metformin, acarbose or rosiglitazone can prevent or delay the progression of IFG and IGT 
to type 2 diabetes in high-risk patients with obesity or overweight,21-27 with more extensive 
Type 1 diabetes accounts for 5-10% of all diabetes. It is an autoimmune disease that 
destroys the beta cells in the pancreas, usually leading to an absolute insulin deficiency. 
The aetiology is not fully understood, but it is considered to be a combination of genetic 
predisposition and environmental factors.9
Type 2 diabetes accounts for 90% of all diabetes. The disease involves a successive 
increase in insulin resistance and a gradual decrease in beta-cell function with a relative 
insulin deficiency. The aetiology is complex, with the co-existence of abdominal obesity, 
hypertension, hyperlipidaemia, physical inactivity, smoking and a genetic predisposition.9
Gestational diabetes is defined as hyperglycaemia with onset during pregnancy and 
is present in approximately 2% of all pregnant women in Sweden.10 Women with 
gestational diabetes run an increased risk of developing type 2 diabetes later in life.9,11
Other forms of diabetes include genetic disorders, such as defects in beta-cell function or 
insulin action and diseases of the exocrine pancreas (such as cystic fibrosis) or induced 
by drugs.9
 Figure 2. Four main types of diabetes according to the American Diabetes Association.9
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evidence for IGT than IFG. Patients with impaired glucose regulation run an increased risk 
of cardiovascular disease (CVD) which has been suggested by some to be stronger for IGT 
than IFG, possibly explained by the closer relationship to the metabolic syndrome or to the 
higher glucose levels that identify IGT compared with IFG.28-30
Classification of diabetes and diagnostic considerations 
The currently used criteria for glucose abnormalities according to the WHO are presented 
in Table 1.7,8  In 2011, the WHO stated for the first time that HbA1c ≥6.5 DCCT (IFCC ≥48 
mmol/mol) could be used as a diagnostic test for diabetes mellitus in addition to fasting 
blood glucose and the OGTT, where the criteria have remained unchanged since 1999.8 
While the WHO does not state any level of HbA1c as being consistent with “prediabetes”, 
the American Diabetes Association (ADA) has introduced 5.7-6.4% DCCT (IFCC 38-47 
mmol/mol) as a cut-off point for prediabetes.9 
Risk factors for type 2 diabetes
The prevalence of type 2 diabetes is related to age and ethnicity. Approximately 50% of 
patients with type 2 diabetes are older than 60 years.31 The prevalence of type 2 diabetes 
in Sweden is 4-7% compared with 50% in Pima Indians.31,32 Other risk factors associated 
with diabetes include heredity, obesity (especially visceral adiposity), physical inactivity, 
smoking, hypertension, dyslipidaemia with hypertriglyceridaemia and low HDL 
cholesterol.33,34 Patients who eventually develop type 2 diabetes usually present with several 
of these risk factors. The term “metabolic syndrome” is used as a state with a clustering of 
several of the previously listed risk factors, with and without established diabetes. There are 
several definitions of metabolic syndrome but it typically includes hypertension, visceral 
adiposity, hyperinsulinaemia, disturbed glucose regulation, increased inflammatory activity, 
hypofibrinolysis and dyslipidaemia.6
Diabetes a global disease
The global prevalence of diabetes is 8.5% in the adult population.35 According to the 
International Diabetes Federation 415 million adults around the world suffered from diabetes 
Table 1. Criteria for the diagnosis of diabetes mellitus and other categories of hyperglycaemia 
according to the WHO in 2006 and 2011.7,8
                 Glucose concentration (mmol/L)
Plasma 
venous
Plasma 
capillary
Whole blood 
capillary
HbA1c
mmol/mol
Diabetes mellitus* ≥48
   Fasting and/or ≥7.0 ≥7.0 ≥6.1
   two-hour post-glucose load ≥11.1 ≥12.2 ≥11.1
Impaired glucose tolerance 
   Fasting and <7.0 <7.0 <6.1
   two-hour post-glucose load 7.8-11.0 8.9-12.1 7.8-11.0
Impaired fasting glucose 
   Fasting 6.1-6.9 6.1-6.9 5.6-6.0
*If asymptomatic, an additional glucose test is required to confirm the diagnosis.
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in 2015 and another 318 million had IGT.32 These figures are estimated to rise to 642 million 
living with type 2 diabetes in 2040 due partly to increased longevity but also influenced by 
an unhealthy lifestyle with the overconsumption of food, an inappropriate dietary pattern 
and decreased physical activity. As diabetes is a major risk factor for developing premature 
atherosclerosis and CVD, this pandemic is of serious concern not only for the individual but 
also for society causing a major increase in health-care costs. 
Pathophysiology and complications of diabetes 
The pathophysiology of type 2 diabetes comprises a genetic predisposition to develop insulin 
resistance in peripheral tissues, mainly the liver and muscles, which is further enhanced 
by obesity and physical inactivity. To bridge this, the pancreatic beta cells are prompted 
to increase their production of insulin. Normoglycaemia is preserved as long as the beta 
cells are able to augment secretion, creating a hyperinsulinaemic state. With time, the 
beta-cell function becomes compromised thereby reducing the production of insulin. As a 
consequence, the postprandial glucose and subsequently also the fasting glucose levels are 
elevated. This is referred to as Starling’s curve of the pancreas.36 Studies report that patients 
with IGT have already lost approximately 80% of their beta-cell function.37 The failing 
pancreatic beta cells combined with the enhanced insulin resistance in the skeletal muscles 
and liver are often referred to as “the triumvirate”.36 This concept has been further expanded 
to “the ominous octet”, including more recently identified dysfunctional metabolic systems 
including the adipose tissue with accelerated lipolysis, the gastrointestinal tract with incretin 
deficiency and resistance, the kidney with increased glucose re-absorption, the pancreatic 
alpha cells with hyperglucagonaemia and the brain with insulin resistance (Figure 3).37
Figure 3. The ominous octet. HGP=Hepatic glucose production. Adapted with permission from 
DeFronzo.37
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It is proposed that obesity and insulin resistance are complexly linked together by 
inflammation. In the presence of obesity, there is an imbalance between energy input and 
output with a state of nutrient excess triggering responses in several cell types such as 
vascular endothelial cells,38 hepatocytes,39 myocytes,40 adipocytes,39 and macrophages. This 
stimulates the production of reactive oxygen species (ROS) and proinflammatory cytokines, 
including tumor necrosis factor-α (TNF-α),41,42 leptin,43 adiponectin, interleukin-6 (IL-
6),44 resistin45 and plasminogen activator inhibitor-1 (PAI-1),46 eventuating the creation of 
oxidative stress (Figure 4).47 Further, the endoplasmatic reticulum, which processes proteins 
into their mature form, becomes affected with an accumulation of fatty acid metabolites as 
a response.39,40 This chain of events further enhances inflammation and increases insulin 
resistance through the activation of the IkappaB kinase-beta (IKKb)/ nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB) pathway (where NFkB translocation leads 
to the increased expression of inflammatory markers and mediators) and the jun n-terminal 
kinase (JNK) pathway (which blocks the action of insulin by the phosphorylation of insulin 
receptor substrate-1).48,49 The hypothalamic response to insulin and leptin may also be 
impaired due to an affected JNK pathway, resulting in an incapacity to detect the ongoing 
increase in adipose tissue as the brain perceives the amount of body fat to be stable.50-52
Hyperglycaemia and atherosclerosis
Atherosclerosis is accelerated in the presence of hyperglycaemia and it is suggested that 
type 2 diabetes and atherosclerotic vascular disease may share a common background, “the 
common soil” theory, which includes inflammation and increased oxidative stress.53 As the 
antilipolytic effect of insulin is impaired in type 2 diabetes there is an excess of free fatty 
Figure 4. Hypertrophic adipocytes, cytokine-mediated inflammation and the progress of  
atherosclerosis. Reproduced with permission from Hajer et al.47
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acids resulting in oxidative stress via the increased production of reactive oxygen species54 
and vasoconstrictors (such as endothelin-1)55 and the impaired production of nitric oxide,56 
leading to a defective smooth muscle cell function with vasoconstriction. Dyslipidaemia 
in diabetes includes hypertriglyceridaemia, low HDL and an excess of small dense LDL 
particles which are prone to oxidation.57 Oxidated LDL is consumed by macrophages with the 
formation of foam cells58 in the intima, causing cytokine-mediated increased inflammation 
and the acceleration of the atherosclerotic process.59 Smooth muscle cells are influenced 
by cytokines and migrate to form a fibrous cap which in the presence of inflammation and 
decreased collagen production becomes thin,60 increasing the risk of plaque rupture. Platelet 
aggregation is increased with an enhanced expression of glucoprotein Ib-, IIb/IIa mediating 
platelet-fibrin interaction61 and with an increased concentration of such factors as PAI-162 
inducing a prothrombotic environment.
Adiponectin 
Adiponectin is an adipokine secreted from the adipose tissue. The levels are genetically 
influenced, increased with age and female gender and are inversely associated with body 
fat percentage.63,64 In a general population without severe or chronic disease, adiponectin 
ranges from 2-26 μg/ml with 1.5 times higher levels in women compared with men (mean 
levels of 7.3 μg/ml in men and 11.9 μg/ml in women).65 Adiponectin assembles to form 
larger molecules and circulates in three isoforms: low-, medium- and high-molecular-weight 
adiponectin. Data on the prognostic role of the proportion of isomers are conflicting.66-68 
Adiponectin functions mainly through two receptors,69 AdipoR1 (abundant in skeletal 
muscle) and AdipoR2 (abundant in liver), with the subsequent activation of AMP-activated 
protein kinase70 and PPAR-α71 resulting in improved glucose metabolism and increasing 
insulin sensitivity but also stimulating the oxidation of free fatty acids (FFA) and decreasing 
plasma triglycerides.72 Experimental data indicate that adiponectin also has anti-inflammatory 
and anti-atherogenic73 effects including the reduced expression of adhesion molecules in 
endothelial cells,74 the reduced proliferation and migration of smooth-muscle cells75,76 
and the inhibited transformation of macrophages to foam cells (Figure 4).77 Low levels of 
adiponectin are related to the metabolic syndrome,78 dyslipidaemia,79 insulin sensitivity 
and diabetes80 and have been associated with coronary atherosclerosis and myocardial 
infarction.81,82 However high levels are related to mortality.83,84 That low levels predict 
myocardial infarction in healthy individuals while high levels are associated with increased 
mortality after a myocardial infarction has been referred to as “the adiponectin paradox”.85 
The mechanisms behind this paradox are not fully understood but several possibilities have 
been presented. Plasma brain natriuretic peptide (BNP) and cytokines have been suggested 
as key determinants of adiponectin by regulating its release from adipose tissue, possibly 
influenced by the degree of activated systemic inflammation.86 In a state of low-grade 
inflammation, as in an ongoing silent atherosclerotic process without significant CVD, 
adiponectin may be suppressed while it is driven upwards by circulating BNP in patients 
with advanced CVD.86 There are also data indicating that adiponectin may be associated with 
severe co-morbidity and cachexia.87,88 Furthermore, elevated levels of adiponectin can be 
caused by dysfunctional or down-regulated adiponectin receptors in obesity-induced insulin 
resistance.71,89 Adiponectin may be increased by physical activity and treatment with statins, 
PPAR γ or α agonists, RAAS blockade, some calcium channel blockers and β-blockade.90
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Leptin
Leptin is an adipokine that is mainly expressed in adipose tissue but also in the heart, vessels, 
bone marrow, placenta, skeletal muscles and brain. Six isoforms of the leptin receptor have 
been described and they are variously expressed in different tissues.91 If there is a balance in 
energy intake and output the leptin levels reflect total body fat mass. Following 24 hours of 
fasting, the leptin levels decrease by 30%. The levels will rise by about 50% after 12 hours of 
overfeeding.92 Leptin production is decreased by statins,93 fibrates94 and thiazolidinediones.95 
The first detected leptin effect was regulation of body weight by decreasing food intake and 
increasing thermogenesis mediated via a hypothalamic influence.96-98 It was subsequently 
demonstrated that leptin influenced carbohydrate and lipid metabolism and the reproductive 
system.99 In addition, leptin is associated with several components of the atherosclerotic 
process such as endothelial dysfunction, oxidative stress, sympathetic activation and 
thrombogenicity.100,101 It is not fully understood whether this is a direct pro-atherogenic 
effect of leptin or whether it reflects a state of leptin resistance.102-104 It has been speculated 
that a selective leptin resistance may occur, explaining why appetite is not depressed in 
obese individuals, while autonomic and cardiovascular actions are still stimulated by 
hyperleptinaemia.103 Leptin resistance has also been proposed as a mechanism behind the 
poor effect of recombinant leptin in obese patients.105 High levels of leptin can inhibit the 
insulin receptor, resulting in impaired insulin-mediated glucose transport, hyperglycaemia 
and insulin resistance.106 Hyperleptinaemia may also induce hyperinsulinaemia and insulin 
resistance by intensifying free fatty acid oxidation107 which stimulates insulin secretion and 
impairs insulin receptor signalling.108 Leptin levels are higher in females than males.109 The 
gender differences observed in both adiponectin and leptin are not fully explained. Oestrogen 
stimulates leptin secretion from adipocytes111,112 in women and there is a negative correlation 
between testosterone and leptin in men.113 In addition to these sex hormone differences,110 
the distribution of body fat114 and dissimilarities in the blood-brain barrier between men and 
women have been proposed.115,116 Unlike adiponectin, leptin is associated with cerebrovascular 
disease.117 Increased levels of leptin have been associated with CVD in some118-120 but not all 
studies.121-123 There are also contradictory data in patients with diabetes.124,125 It has been 
speculated that the role of leptin in CVD may be as complex as that of adiponectin with a 
paradoxical relationship similar to the already highlighted adiponectin paradox.126 
Microvascular complications of diabetes
Microvascular complications related to type 1 and type 2 diabetes include retinopathy, 
nephropathy and neuropathy. They are related both to the duration of diabetes and to the 
severity of hyperglycaemia. In 1993 the Diabetes Control and Complications Trial (DCCT) 
established that strict glucose control is of major importance in reducing microvascular 
complications in type 1 diabetes127 and in 1998 the UK Prospective Diabetes Study (UKPDS) 
showed that glucose control reduced microvascular complications in type 2 diabetes.128 
Other important strategies to reduce microvascular complications include renal protection 
via blood-pressure and microalbuminuria control in order to avoid end-stage renal disease, 
the screening of and early laser therapy of retinopathy protecting from blindness and 
preventive foot care reducing the risk of amputation. The prevalence of diabetic nephropathy 
in patients with end-stage renal disease in Sweden is 25%.129 Diabetes neuropathy includes 
autonomic dysfunction in several organ systems including the cardiovascular system, which 
is associated with an increased risk of silent myocardial ischaemia and sudden death.130 
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The presence of microvascular complications may therefore not only be related to small 
vessel disease but also have an influence on macrovascular complications. 
Macrovascular complications of diabetes
The risk factors for developing macrovascular disease in type 2 diabetes are the same as 
for people without diabetes although more pronounced. It is estimated that 90% of the risk 
factors for CVD are modifiable, with diabetes as one of them, increasing the risk two to four 
times.131 The risk of macrovascular complications such as coronary heart disease (CHD= 
acute coronary syndrome [ACS]; sudden cardiac death, angina pectoris), peripheral vascular 
disease and ischaemic stroke are related to insulin resistance. The risk starts several years 
before the diagnosis of diabetes and prior to the development of microvascular disease (Figure 
5). There is a gender difference where diabetes triples the risk of incident CHD in women 
and doubles the risk in men.132 The mechanism behind the higher risk for women is not fully 
understood. A more extensive risk factor burden already in the prediabetic state133,134 with 
higher BMI in women than men135,136 and a suboptimal management has been proposed137 
with women less likely to achieve the recommended treatment targets for cardiovascular 
risk factors than men.138 In patients with diabetes the risk of developing CVD is related to 
fasting blood glucose and HbA1c.139-141 There is a U-shaped relationship between the level of 
glycaemia and mortality with an increased risk of both low and high levels.142-144 
Mortality causes in individuals with diabetes are to a large extent cardiovascular, while 
purely diabetes-related complications are less common since the introduction of insulin.145 In 
Sweden, cardiovascular reasons have long been the dominant mortality cause in people both 
with and without diabetes. During the last twenty years, mortality due to cardiac disease has 
decreased by around 50% thereby increasing longevity (Figure 6).  Meanwhile, cancer has 
become almost as common a reason for mortality as cardiovascular disease.146 The prognosis 
after myocardial infarction has improved in patients both with and without diabetes but the 
one-year mortality is still about 30% higher in a patient with diabetes.
Prediabetes Diabetes
Insulin resistance
Insulin production
Fasting blood glucose
Macrovascular
complications
Microvascular
complications
Time
Years to
decades Typical time-point for diagnosis of diabetes
Figure 5. The natural history of dysglycaemia from prediabetes to diabetes and its relationship to 
macro- and microvascular complications. Importantly, macrovascular complications precede the 
defined point for the diagnosis of diabetes. Adapted with permission from Laakso et al.31
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Glucose abnormalities in myocardial infarction
Hyperglycaemia during an acute myocardial infarction (AMI) was first described in 1929147 
and was interpreted as a result of stress,148 related to the severity of the infarction149 and 
left ventricular failure.150 In 1966, glucose disturbances detected by an intravenous glucose 
tolerance test were linked with a dismal prognosis after AMI151 and trials attempting to 
improve glucose tolerance with oral hypoglycaemic drugs were conducted.152,153 These 
attempts were abandoned when the University Group Diabetes Program study indicated that 
the administration of tolbutamide was associated with increased cardiovascular mortality as 
compared to treatment with diet alone or diet plus insulin.153 
Since the 1960s, many variations of a glucose tolerance test have been applied with different 
routes of administration, different doses of glucose and different intervals of sampling. In 
1980, the OGTT was standardised by the WHO.154 Around 20% of patients with AMI suffer 
from diabetes.155 When such patients without previously known glucose perturbations were 
investigated with a standardised OGTT as in the GAMI study another 1/3 had previously 
undetected diabetes and 1/3 IGT.156 These results have since then been repeated.157,158 The 
timing of the OGTT is crucial; when tested already two days after the acute onset, the test 
may capture an acute stress reaction159 which is the reason for performing the OGTT no less 
than four to five days after an AMI. There are indications that patients with newly detected 
glucose abnormalities run an increased risk of a future cardiovascular event the first year after 
an AMI but studies on long-term outcome are lacking.160-163 
The cardiovascular impact of glycaemic intervention
In 1963 Sodi-Pallares proposed the use of an infusion of glucose-insulin-potassium (GIK) in 
patients with AMI with the aim of promoting electrical stability and preventing arrhythmias 
by facilitating the transportation of potassium into the myocardial cell (Figure 7).164 Since then 
GIK,165 glucose-insulin141 or only insulin166 has been used to impede the metabolic vicious 
circle in the oxygen-deficient state caused by a coronary occlusion in AMI. In addition, pain 
and dyspnoea enhance the sympathetic drive increasing myocardial ischemia and FFA in 
Figure 6. Trends in mortality causes in Sweden in 1992-2012. Adapted with permission from 
reference 146.
Women Men
Numbers per 100 000 Numbers per 100 000
Other
Cancer
Alcohol
Stroke
Accidents
Cardiac disease
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plasma167 and the myocardial uptake and beta-oxidation of FFA. Via an accumulation of fatty 
acyl CoA, glycolysis is suppressed, with further ischaemic damage to the tissue and a risk 
of arrhythmia as a consequence.167 The GIK concept was therefore introduced to improve 
glycolysis and reduce the more oxygen-consuming beta-oxidation.
Reducing hyperglycaemia by means of an intensified, insulin-based glycaemic control 
compared with conventional treatment improved survival in patients with AMI in the first 
DIGAMI study141 and in some, but not all studies, in patients in general intensive care.166,168 
Further attempts to reduce cardiovascular mortality and morbidity by means of isolated 
glucose-lowering therapy based on insulin or oral glucose-lowering drugs were 
disappointing.169-173 The UKPDS study randomised 3867 patients with newly diagnosed 
type 2 diabetes at low cardiovascular risk to intensified glycaemic control with insulin or 
sulphonylurea compared with conventional diet-based treatment studying the effect on 
micro- and macrovascular complications.128 Despite an overall reduction in HbA1c of 0.9% 
(9.8 mmol/mol) with intensive compared with conventional therapy, there was no significant 
difference (p=0.052) in cardiovascular endpoints during the initial 10 years of follow-up.128 
Only obese patients on intensive therapy with metformin experienced a significant reduction 
in mortality and cardiovascular events.174 However, in a further long-term follow-up, 10 
years after the cessation of randomised treatment, an initial, tight glycaemic control was 
associated with cardiovascular benefits despite a convergence of HbA1c levels over time (the 
so-called “legacy effect”).140 More recent randomised trials, Action in Diabetes and Vascular 
Figure 7: Metabolic pathways in the cardiomyocyte and metabolic effects of glucose-insulin-
potassium (GIK). Printed with permission from Grossman et al.167
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Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE)169 
and Action to Control Cardiovascular Risk in Diabetes (ACCORD),170 enrolled high-risk 
patients of whom approximately one third had a history of a major cardiovascular event. 
Intensive glycaemic control aiming at almost normal glucose levels failed to show any 
macrovascular benefits, despite a high event rate, and was even associated with increased 
mortality in the ACCORD study.170,175 These results have further highlighted the temporal 
aspects of glucose control raising concern that glycaemic control may be important in the 
early stages of the disease but less so in cohorts with longstanding diabetes and already 
established CVD.176 Furthermore, too tight glucose control has been questioned as it increases 
the risk of hypoglycaemia which may promote cardiovascular events. 
Recent reports including new types of glucose-lowering drugs, such as an SLGT2 inhibitor in 
the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients 
(EMPA-REG OUTCOME)177 and the GLP-1 receptor agonists liraglutide in Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)178 
and semaglutide in the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with 
Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6)179 trials, all including patients 
with type 2 diabetes at high cardiovascular risk, are promising. There was a statistically 
significant reduction in mortality and cardiovascular events when glucose-lowering therapies 
with empagliflozin,177 liraglutid178 and semaglutide179 were added to standard therapy during 
two - three years of follow-up. These contradictory results regarding the cardiovascular 
outcome indicate that the choice of glucose-lowering drug is of importance when aiming 
for cardiovascular-safe therapies in diabetes treatment. Since 2008, the US Food and Drug 
Administration (FDA) has requested that all glucose-lowering drugs should be evaluated 
regarding not only their glucose-lowering effects but also their cardiovascular safety effects.180
The risk of hypoglycaemia
Hypoglycaemia, often defined as a fasting plasma glucose of <3.9mmol/L accompanied 
by symptoms, is classified into mild (self-treatable) and severe hypoglycaemia (an episode 
that requires external assistance for recovery). The potential cardiovascular effects of 
hypoglycaemia are described in Figure 8.181 Hypoglycaemia activates the sympatico-
adrenal system with the release of epinephrine and nor-epinephrine increasing cardiac 
workload while at the same time decreasing the arrhythmia threshold. Electrocardiographic 
changes including a lengthening of the QT interval can be seen182 (Figure 9) and ventricular 
tachycardia has been described.183 In addition, hypoglycaemia stimulates platelet activation 
and abnormalities in coagulation.184 Like hyperglycaemia, hypoglycaemia also causes 
oxidative stress and endothelial dysfunction.185  If recovery occurs with normoglycaemia the 
harmful effects are diminished. However, if hyperglycaemia succeeds hypoglycaemia the 
inflammatory response is enhanced and the endothelial function further impaired.186
The impact of coronary interventions
Important landmark events in the management of patients with coronary artery disease (CAD; 
Figure 10) are the development of coronary angiography by Sones in 1958,187 coronary artery 
bypass grafting (CABG) by Favaloro in 1967188 and percutaneous coronary intervention 
(PCI) in 1977 by Grünzig.189 The first coronary stent implantation was performed in 1986 
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Figure 8. Overview of the potential cardiovascular effects of hypoglycaemia. Adapted with permission 
from Desouza et al.181
610 ms456 ms
A B
mV mV
Figure 9. The QT interval during normoglycaemia (A) and induced hypoglycaemia (B). Adapted with 
permission from Marques et al.182
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by Puel,190,191 using a self-expanding stent, while a balloon-expandable stent was first used in 
1987 by Palmaz.192 Several studies have demonstrated the superiority of coronary angioplasty 
over thrombolytic therapy in AMI in terms of mortality and left ventricular function, where 
angioplasty is associated with fewer re-infarctions and intracranial haemorrhages.193,194 For 
moderate- and high-risk patients with unstable CAD there is a significantly lower mortality 
rate with early invasive treatment compared with non-invasive treatment.195-197 With improved 
technology and treatments a lower complication rate is seen. Studies performed before the 
use of stents revealed a very high restenosis rate, 32-46% within one year, in patients with 
diabetes.198-200 The use of bare metal stents (BMS) and drug eluting stents (DES) reduced the 
rate of restenosis to around 5% during the first year.201,202 DES prevent restenosis through 
the suppression of tissue growth at the stent site and local modulation of the inflammatory 
responses and the immune system with a substantially lower restenosis rate in patients with 
diabetes compared with BMS.203 In spite of this, modern technology with the use of DES has 
not been able to abolish the negative impact of diabetes on mortality204 and restenosis. Due 
to a lower long-term mortality rate and fewer major coronary events CABG is still preferred 
to PCI in patients with multivessel disease, in particular in the presence of diabetes.205-207 
There may be several reasons, including that patients with diabetes respond less well to 
antithrombotic treatment and that hyperglycaemia during and after the intervention may be 
related to an increased propensity for restenosis.
Summary and gaps in knowledge
Patients with diabetes run an increased risk of CVD.131 Despite improved management 
during the past twenty years the longevity after a cardiovascular event is still compromised 
compared with patients without diabetes.204 In the Swedish general population, cardiovascular 
Year
Important events in diabetes management
1903 1940 20161960 1970 1980 1990
Important events in ACS management
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Figure 10. Landmark events in diabetes and ACS management.
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mortality has decreased significantly during the last few decades.146 The question of whether 
this is true for patients with diabetes is less well explored. Furthermore, the complication 
pattern after AMI apart from mortality is poorly evaluated. Information on mortality and 
complication pattern is important in order to find ways further to improve quality of life and 
life expectancy among patients with diabetes. Not only diabetes but also unknown glucose 
abnormalities, which are common in patients with AMI,156 appear to affect the short-term 
prognosis.160-163 The question of whether this is also important in the long-term perspective 
has not been fully explored.
The mechanism behind the cardiovascular complications related to glucose abnormalities is 
not completely understood. Insulin resistance and atherosclerotic vascular disease are closely 
linked by an unhealthy distribution of adipose tissue and an increased degree of systemic 
inflammation53 with dysregulated adipokines. Both adiponectin and leptin are biomarkers 
that are easily available and can be measured in the setting of an acute coronary event. These 
biomarkers can possibly identify high-risk patients and also contribute to an understanding 
of the underlying pathophysiology. Data on the prognostic implications of adipokines in 
patients with prevalent CHD are contradictory and long-term outcome studies are lacking.
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AIMS
The overall aim
The overriding aim of this thesis is to increase knowledge of patterns of cardiovascular 
complications and mortality causes after coronary events in patients with diabetes. Moreover, 
the intention is to investigate the impact of undetected glucose abnormalities and glucose 
control on prognosis in patients with acute myocardial infarction in order to identify 
opportunities to improve their long-term outcome.
Specific aims
1. To investigate the lasting effect of glucose control on mortality after acute myocardial 
infarction in patients with diabetes randomised to intensified, insulin-based glucose 
control or conventional treatment (Study I)
2. To analyse the long-term prognosis and morbidity patterns after acute myocardial infarction 
in patients with and without newly discovered glucose abnormalities (Study II)
3. To evaluate the predictive power of HbA1c and the oral glucose tolerance test for future 
cardiovascular events in patients with acute myocardial infarction without previously 
known diabetes (Study II)
4. To investigate complication patterns after a first percutaneous coronary intervention in 
unselected patients with diabetes and to identify high-risk diabetes individuals (Study III)
5. To investigate mortality causes after coronary events in patients with and without diabetes 
or newly discovered glucose abnormalities (Study I, II, III)
6. To analyse the significance of adiponectin and leptin as biomarkers of long-term 
cardiovascular complications in patients with acute myocardial infarction and newly 
discovered glucose abnormalities (Study IV)
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MATERIAL AND METHODS
This thesis is based on three study populations with different designs, sizes, diabetes 
prevalence and study periods as summarised in Table 2. 
Definitions 
During the study period, the definition of diabetes and of myocardial infarction has changed 
and consequently varies in the different studies.
Diabetes mellitus and impaired glucose tolerance
In Study I, patients were defined as having diabetes if they had previously been informed 
of the diagnosis and prescribed treatment with diet, oral drugs or insulin. Patients without 
the diagnosis but with blood glucose of  ≥11 mmol/L at admission were regarded as newly 
detected diabetes. In Study I, diabetes criteria from 1979 were used.208 
In Studies II and IV, diabetes was defined according to the WHO criteria from 1999 (Table 1).6 
In Study III, diabetes was considered to be present if the patient had been hospitalised 
for diabetes at any time in the National Patient Register or was registered in the Swedish 
Coronary Angiography and Angioplasty Registry (SCAAR) as having diabetes or was 
receiving treatment with diet, oral glucose-lowering treatment, or insulin according to the 
Prescribed Drug Register.
Table 2: Overview of the four studies that form the basis of this thesis.
Study I II  III IV
Cohort name DIGAMI GAMI SCAAR GAMI
Study design Randomised 
controlled trial
Case-control study Register study Cohort study
Number of patients 620 167 58 891 180
Number of controls - 184 - -
Age at inclusion 
(years, mean)
68 63 (patients)
64 (controls)
67 64
Recruitment years 1990-1993 1998-2002 2006-2010 1998-2000
Inclusion event AMI AMI (patients)
No AMI (controls)
First PCI AMI
Proportion with 
diabetes
100% 0% 19% 0%
Follow-up period 
(years, mean (SD))
7.3 ± 6.6 10.2 ± 3.5 (patients)
9.9 ± 1.7 (controls)
2.5 ± 1.5 9.9 ± 3.8
Outcome Mortality Mortality
Cardiovascular events
Mortality
Cardiovascular events 
Mortality
Cardiovascular events
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Abnormal glucose tolerance
Abnormal glucose tolerance (AGT) was classified as either IGT or diabetes.
 
Acute myocardial infarction
In Study I, the diagnosis of AMI was based on the WHO criteria from 1979.209 At least 
two of the following criteria had to be fulfilled to be classified as a definite AMI: (1) chest 
pain for ≥15 minutes; (2) ≥2 values of serum creatine kinase (S-CK) and serum creatine 
kinase isoenzyme B (S-CKB) or serum lactic dehydrogenase (S-LD) above the normal range 
(normal+2 SD), including an LD-isoenzyme pattern typical of myocardial damage; and (3) 
development of new Q waves in ≥2 standard ECG leads. The diagnosis of possible AMI 
was used if typical chest pain was accompanied by only one S-CK or S-LD value above the 
normal range and/or new Q waves in one ECG lead only. 
In Studies II and IV, the diagnosis of AMI was based on the joint recommendations from the 
ESC and ACC from 2000.210 Acute, evolving or recent myocardial infarction was diagnosed 
if one of the following criteria was fulfilled: (1) Typical rise and gradual fall (troponin) or 
more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least 
one of the following: (a) ischaemic symptoms; (b) development of pathological Q waves on 
the ECG; (c) ECG changes indicative of ischaemia (ST segment elevation or depression); 
or (d) coronary artery intervention (coronary angioplasty); (2) Pathological findings of an 
AMI. To consider established myocardial infarction, any one of the following criteria had to 
be satisfied: (1) Development of new pathological Q waves on serial ECGs. The patient may 
or may not remember previous symptoms. Biochemical markers of myocardial necrosis may 
have normalised, depending on the length of time that has passed since the infarct developed. 
(2) Pathological findings of a healed or healing myocardial infarction.
In Study III, the diagnosis of myocardial infarction was set by the physician in charge based 
on the International Classification of Diseases (ICD-10) codes as apparent in the Swedish 
National Patient Register.
Re-infarction 
In Studies I, II, and IV, re-infarction was defined as a new AMI >72 hours after the index 
infarction. In Study III, a re-infarction was based on ICD-10 codes in the Swedish National 
Patient Register after discharge from the index PCI. 
Stroke
In Studies II and IV, stroke was classified according to the WHO as a neurological deficit 
observed by a physician and persisting for >24 hours without any other disease explaining 
the symptoms.211 In Study III, stroke was based on ICD-10 codes in the Swedish National 
Patient Register after discharge from the index PCI.
  
Severe congestive heart failure
In Studies II and IV, severe congestive heart failure (CHF) was defined as clinician-judged 
heart failure necessitating hospital admission including intensified treatment. In Study III, the 
diagnosis of CHF was based on the ICD-10 codes in the Swedish National Patient Register.
Restenosis and stent thrombosis
Restenosis and stent thrombosis (Study III) were diagnosed if a cardiovascular event resulted 
in hospitalisation. A restenosis was then defined as a clinically relevant stenosis (>50%) or 
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as a significant reduction in fractional flow reserve (<0.80) in a previously treated vessel 
segment.202A stent thrombosis was defined as an angiographically verified occlusion or 
visible thrombus in a previously implanted stent. 
Study subjects and protocols
Study I
Patients
Patients with diabetes or with a blood glucose concentration of  >11 mmol/L admitted to the 
coronary care units at 19 Swedish hospitals between 1 January 1990 and 31 December 1993 
with a suspected AMI in the previous 24 hours were included in the DIGAMI trial. Patients 
unable or unwilling to participate, living outside the catchment area, enrolled in other studies 
or already in DIGAMI were excluded. Of 1240 eligible patients, 620 were excluded, leaving 
620 patients as the study population. Before randomisation, subjects were classified as being 
at high cardiovascular risk if they fulfilled two or more of the following criteria: age >70 
years, previous myocardial infarction, a history of CHF and present treatment with digitalis. 
On the basis of this classification and if they had been prescribed insulin previously or 
not, the patients were divided into one of four predefined strata; I: no insulin and low risk 
(n=272); II: no insulin and high risk (n=129); III: insulin and low risk (n=119); or IV: insulin 
and high risk (n=100).
Protocol and hypothesis
DIGAMI 1 tested the hypothesis that a rapid improvement in metabolic control by insulin-
glucose infusion decreases the high initial mortality and that continued strict metabolic 
control aiming at normoglycaemia improves the subsequent prognosis in patients with 
diabetes and AMI.
The study was designed as a prospective, randomised, open-label trial with blinded endpoint 
evaluation (PROBE). Patients were randomly assigned (1:1) to either intensified insulin-
based glycaemic control for at least three months (intensified group; insulin-glucose infusion 
≥24 h followed by subcutaneous multidose insulin treatment), or to serve as a control group 
receiving conventional glucose-lowering treatment according to the attending physician. 
Patients were seen at three and 12 months after randomisation. The primary endpoint was 
mortality after three months in the original trial and all-cause mortality in the present long-term 
follow-up (Study I) following all patients until 31 December 2011. Death certificates were 
obtained from the Swedish Cause of Death Register and mortality causes were subsequently 
categorised according to the ICD-9 and ICD-10 codes, as set by the physician in charge, into 
eight classes of mortality causes (cardiovascular, cancer, infections, renal failure, sudden 
death, diabetes mellitus, dementia/old age or other). All mortality causes were scrutinised 
and were finally classified by two research physicians blinded to randomised treatment. 
Studies II and IV
Patients
Studies II and IV are based on the Glucose Tolerance in Patients with Acute Myocardial 
Infarction (GAMI) trial. A total of 181 patients with AMI without previously known diabetes 
and admission capillary blood glucose of <11.1 mmol/L admitted to the coronary care units 
at the Karolinska and Västerås Hospitals between 1998 and 2000 were enrolled in the study. 
The exclusion criteria were age >80 years and serum creatinine of >200 µmol/L. One patient 
was lost to follow-up. In Study II, only patients whose glucose tolerance was assessed were 
included. Thirteen patients were not investigated with an OGTT at discharge due to death 
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during hospitalisation (2), refusal (2), illness (7) or technical problems (2), leaving 167 
glucometabolically classified patients as the final study cohort. Study IV included all 180 
patients.
 
Controls
Age-, gender- and catchment area-matched controls (n=185) without a prior diagnosis of 
diabetes or CVD (apart from mild hypertension) or any acute illness during the preceding 
three months were recruited between 2001-2002. One control was lost to follow-up, leaving 
184 as the final study cohort in Study II. In all, 500 controls were invited by letter after 
matching for age and gender, of whom 80 were excluded due to previous diseases, 150 did 
not respond, 72 were unwilling, four died and eight were living outside the catchment area.  
Protocol and hypothesis
Study II tested the hypothesis that newly identified AGT constitutes an important marker of 
long-term outcome, while Study IV tested the hypothesis that low levels of adiponectin but 
high levels of leptin were associated with a future cardiovascular event after an AMI in patients 
without previously known diabetes.
A prospective study design was adopted with the consecutive enrolment of patients apart from 
during summer vacations and weekends. All patients were treated for their AMI according to 
established national and international guidelines at that time which mainly included reperfusion 
therapy with thrombolysis. An OGTT was performed on the day of hospital discharge 4-5 days 
after the AMI in the patients and at the inclusion of the controls. The patients and controls were 
separately followed for cardiovascular events (first of cardiovascular mortality/AMI/stroke/
CHF) and mortality until 31 December 2011. Information on cardiovascular events was derived 
from hospital and outpatient clinical records supplemented if possible by a telephone interview 
with the survivors (or close relatives when needed). Mortality reasons were classified according 
to available hospital records and to the ICD-10 codes on the death certificates obtained from 
the Swedish National Death Registry. The cause of death was subsequently categorised as 
cardiovascular (caused by AMI/stroke/aortic dissection or sudden death without any obvious 
reason), cancer or other after the evaluation of death certificates by two research physicians 
blinded to the OGTT result.
Study II comprises both patients and controls while Study IV only encompasses patients.
Study III
Patients
The patients in Study III were recruited from the SCAAR. Since the start of the registry in 
1998, the SCAAR has collected data on patients undergoing coronary angiography and PCI 
and nowadays it includes the 29 centres performing these procedures. Details on coronary 
angiographies and coronary interventions in the registry are provided by the physicians 
who perform the coronary investigations and/or interventions. Consecutive patients with a 
first performed PCI, included in the SCAAR between 2006 and 2010 and with no previous 
revascularisation (CABG and/or PCI) and with complete information on background 
characteristics and treatment, were included in Study III. Due to incomplete data, 347 patients 
(0.6%) were excluded, leaving 58 891 patients as the final study population. Patients with a 
diabetes diagnosis but no prescription for glucose-lowering therapy were categorised as diet 
treated. Patients with a prescription for insulin were categorised as insulin treated, regardless 
of whether or not insulin was combined with diet or oral glucose-lowering therapy.
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Protocol and hypothesis
Study III tested the hypothesis that patients with diabetes have a higher event rate after a 
first PCI compared with those without diabetes, despite the use of contemporary therapies. 
A second hypothesis was that information on the type of glucose-lowering therapy can be 
indicative of the prognosis following a PCI. 
Patients were followed prospectively until 31 December 2010 for mortality and for 
hospitalisation for the following events; AMI, stroke, heart failure, renal failure, restenosis 
or stent thrombosis in any of the coronary vessels, CABG and new PCI. A composite 
cardiovascular event was defined as the first occurrence of total mortality, hospitalisation for 
AMI, stroke or heart failure. The long-term follow-up was obtained by merging the SCAAR 
database with the Prescribed Drug Register, containing data on dispensed and collected 
drugs, the National Patient Register, containing information on all in-patient care, and the 
Cause of Death Register. Causes of mortality were classified according to the main ICD-10 
code on the death certificate and thereafter categorised into eight main causes of mortality 
(CVD, cancer, endocrine/metabolic disease, respiratory disease, gastrointestinal disease, 
urinary tract disease, infections or other).
No patient among those still resident in Sweden was lost to follow-up.
Laboratory investigations
Studies II and IV
Oral glucose tolerance test
A standardised OGTT with 75 g of glucose dissolved in 200 ml of water was conducted under 
stable conditions after 12 hours of overnight fasting without smoking or physical activity. 
The glucose concentration was measured in the fasting state, after 60 and 120 minutes.
Blood glucose concentrations and other biochemical measurements
Blood samples were collected on the first morning after hospital admission, at discharge 
and three months after the index AMI in the patients and in the fasting state during the 
investigation of controls. Plasma was obtained after centrifugation and stored at -70°C 
pending analyses. 
The glucose concentration during the OGTT was measured in whole capillary blood 
immediately after sampling using a HemoCue® photometer (HemoCue® AB, Ängelholm, 
Sweden). The coefficient of variation was ≤3.5%.
HbA1c was analysed by high-performance liquid chromatography (Mono S) from whole 
capillary blood applied on filter paper (Boehringer-Mannheim Scandinavian AB, Bromma, 
Sweden).212 The upper normal limit was 5.3%, with a coefficient of variation of <3%. The 
values were recalculated to the IFCC standard using the following equation: (10.11 x Mono 
S - 8.90).213 
Plasma insulin and intact proinsulin were quantified with commercially available 
immunoassays (DAKO Ltd, Cambridgeshire, UK). The intra- and interassay coefficients of 
variation were 6% and 7% for insulin and 5% and 6% for proinsulin. 
Insulin resistance was estimated in the fasting steady state using the homeostasis model 
assessment of insulin resistance (HOMA-IR) using the following formula: HOMA-IR= 
(plasma insulin x blood glucose x 1.13)/(22.5x6).214
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The insulinogenic index (IGI) was calculated as the difference between 30 and 0 minutes 
plasma insulin divided by the difference between 30 and 0 minutes plasma glucose.
Plasma leptin and total adiponectin were analysed with a double-antibody radioimmunoassay 
(Linco Res., St Louis, MO, USA). The total coefficient of variation for leptin was 4.7% at 
both low (2-4 ng/ml) and high (10-15 ng/ml) levels. The corresponding values for adiponectin 
were 15.2% at low (2-4 µg/ml) levels and 8.8% at high (26-54 µg/ml) levels. 
Statistical analyses and data management
In Studies I-IV, continuous values are presented as the mean ± standard deviation (SD) or 
median (lower and upper quartile) and categorical variables as numbers and percentages.
In Study I, analyses were performed using the intention-to-treat principle. The significance 
of the differences between the groups was tested with Fisher’s exact test for dichotomous 
variables, the χ² test for non-ordered categorical variables and Student’s t test for continuous 
variables. A Cox’s proportional hazard regression model was used to analyse the impact of 
randomised treatment. To test the proportional hazards assumption, interaction terms between 
log (time) and key variables were fitted into the mortality model and the possibility of a time-
dependent effect of treatment was tested by means of spline curves based on Poisson models.
In Studies II-IV, Cox’s proportional hazard regression models were used to analyse the 
univariate and multivariate prediction of a future event. In Study IV, continuous variables 
were log transformed before analysis to avoid the influence of extreme values. Variables 
considered clinically relevant and with a p<0.05 (Study III) or p<0.10 (Studies II and IV) 
were introduced into the multivariate model. In addition, logistic regression analysis was 
performed in Study IV when the association of adiponectin or leptin with future events 
appeared to be non-proportionally distributed. Kaplan-Meier curves were used to estimate 
the cumulative mortality (Studies I-IV) and time to event (Studies II-IV). In Study IV, the 
predictive value of log-transformed leptin and adiponectin as dichotomised by gender-
specific median levels was analysed by Kaplan-Meier curves.
All p-values reported are two-tailed, with a value of <0.05 accepted as statistically significant. 
The analyses were conducted using the SAS statistical program (SAS version 9.2, 9.4), 
software from SAS Institute, Cary, NC, USA, in Studies I, II and IV and SPSS statistical 
program (SPSS version 20) software from SPSS Inc., Chicago, IL, USA, in Study III. 
Ethical consideration   
All studies were conducted in accordance with the Declaration of Helsinki. The DIGAMI 
protocol (Study I) was approved by the ethical boards at the Universities of Gothenburg, 
Linköping, Lund and Uppsala while the ethical committee at Karolinska Institutet approved 
the extended follow-up.
The ethical board at the Karolinska Institute approved the protocol of Studies II and IV while 
the board at Uppsala University approved the design of Study III.
Before enrolment in DIGAMI (Study I) and GAMI (Studies II and IV), patients gave their 
written, informed consent to participate in the initial study and the follow-up. All patients in 
Study III were informed of their participation in the SCAAR. 
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RESULTS
Study I
Clinical data
Apart from glucose-lowering treatment, there was no significant difference between the 
intensified and the control group in terms of clinical and baseline characteristics (Table 3), in-
hospital or follow-up treatment during the first year. At admission, there were no significant 
differences in blood glucose or HbA1c. As previously reported141 blood glucose during the 
first 24 hours and HbA1c after one year decreased in both groups but significantly more in the 
intensified group (-0.9%; SD 1.9, vs. -0.4%; SD 1.8; p=0.006), especially in stratum I (low 
risk-no previous insulin; -1.3%, SD 1.9, in the intensified group vs. -0.5%, SD 1.9, in controls; 
p=0.012). At the time of hospital discharge, 266 patients (87%) in the intensified group were 
on insulin compared with 135 (43%) in the control group (p<0.001). The corresponding 
percentages were 80% and 45% (p<0.001) after three months and 72% and 49% after one 
year (p<0.001). No information about treatment patterns or glucose control after one year 
was available. 
Table 3. Baseline characteristics by randomised treatment group in Study I.
Intensified 
(n=306)
Control 
(n=314)
p
Clinical characteristics
   Age at randomisation (years; mean ± SD) 67 (9.3) 68 (9.5) 0.371
   Gender (male)  191 (62.4%) 197 (62.7%) 1.000
   BMI (kg/m2) (mean ± SD) 27.3 (4.2) 27.0 (4.4) 0.506
Previous disease
   Myocardial infarction 121 (39.5%) 117 (37.3%) 0.616
   Angina pectoris 176 (57.5%) 164 (52.2%) 0.214
   Hypertension 144 (47.1%) 154 (49.0%) 0.679
   Heart failure 69 (22.5%) 70 (22.3%) 1.000
Diabetes
   Previously unknown 31 (10.1%) 46 (14.7%) 0.109
   Duration (years; mean ± SD) 9.9 (10.7) 1.1 (10.4) 0.865
Glucose-lowering treatment
   None   32 (10.5%) 47 (15.0%) 0.083
   Diet   32 (10.5%) 39 (12.5%)
   Oral 140 (45.8%) 114 (36.4%)
   Insulin 102 (33.3%) 113 (36.1%)
Biochemical variables
   HbA1c at randomisation (% or mmol/mol, mean ± SD) 8.2 (1.9), 75 (10) 8.0 (2.0), 73 (11) 0.218
   Blood glucose at randomisation (mmol/L) 15.4 (4.1) 15.7 (4.2) 0.372
   Blood glucose 24 h after randomisation (mmol/L) 9.6 (3.3) 11.6 (4.1) <0.001
   Blood glucose at hospital discharge (mmol/L) 8.2 (3.1) 9.0  (3.0) 0.004
Data are the mean (SD) or n (%) unless otherwise indicated. Data are presented as Mono S standard (%) and IFCC 
(mmol/mol). 
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Mortality
During a mean follow-up period of 7.3 (range 0-22) years, 271 patients (89%) in the 
intensified group and 285 (91%) in the control group died. The median survival was 7.0 
years (IQR 5.6-7.8) in the intensified group and 4.7 (3.8-5.7) in the control group (HR 0.83; 
95% CI 0.70-0.98, p=0.027). The effect of intensified glycaemic control was apparent during 
eight years, increasing the mean survival by 2.3 years (Figure 11). 
Patients in stratum I (low risk-no previous insulin) experienced a significant survival benefit 
(HR 0.77; 95% CI 0.60-1.00, p=0.048) with an average survival time of 9.4 years (95% CI 
8.3-11.1) in the intensified group vs. 6.9 years (95% CI 4.8-8.2) in the control group (Figure 
12 A). The corresponding HR (95% CI) for patients in stratum II (high risk-no previous 
insulin), III (low risk-insulin) and IV (high risk-insulin) was 1.00 (0.70-1.42, p=0.99), 0.87 
(0.58-1.29, p=0.49) and 0.70 (0.47-1.06, p=0.09) as shown in Figure 12 B-D.
Glucose control at admission predicted long-term mortality in the control group (admission 
blood glucose; HR 1.06; 95% CI 1.02-1.09, and HbA1c; 1.10; 1.03-1.19) but not in the 
intensified group (1.03; 0.99-1.06 and 1.06; 0.99-1.14 respectively) after adjusting for age 
and gender.
Study II
Clinical data
Among 167 patients, 54 (32%) had NGT and 113 (68%) AGT (IGT=58 and diabetes=55). 
Patients with AGT were older (65 vs. 60 years), had more frequent previous CHF (11% 
vs. 2%; p=0.048) and were less often revascularised during their hospital stay (42% vs. 
61%; p=0.028). Among 184 controls, 119 (65%) had NGT and 65 (35%) had AGT (IGT=45 
Figure 11. Time to mortality by randomised treatment group in Study I.
Intensified
ControlP
ro
ba
bi
lit
y 
of
 d
ea
th
 
No. at risk
Control
Intensified
Years after randomisation
0 –
314
306
148
175
87
108
48
61
7
15
0
0
          Glucose abnormalities and cardiovascular disease
33
and diabetes=20). Controls with AGT were older (67 vs. 64 years) and had more frequent 
previous hypertension than those with NGT (29% vs. 12%). Baseline characteristics are 
presented in Tables 4 (patients) and 5 (controls).
Major cardiovascular events and mortality
Fifty-three (32%) patients and 28 (15%) controls died, while 72 (43%) patients and 29 (16%) 
controls suffered a major cardiovascular event during a median follow-up period of 11.6 vs. 
10.4 years. The cardiovascular event rate was highest in patients with AGT while patients 
with NGT and controls with AGT had comparable event rates. Controls with NGT had the 
lowest event rate (Figure 13). 
Prediction models for major cardiovascular events and mortality
Patients
In univariate analyses, AGT was related to a major cardiovascular event (HR 2.46; 95% 
CI 1.37-4.42, p=0.003), while fasting glucose at discharge (p=0.52) and HbA1c were not 
(HbA1c ≥4.7%, p=0.85; HbA1c 4.7%-5.5%, p=0.91; HbA1c ≥5.6%, p=0.74). Further, 
univariate variables with a p-value of <0.10 are described in Figure 14A. 
In the final model (including AGT, age, BMI, previous angina pectoris/previous myocardial 
infarction/CHF/CABG), AGT (2.30; 1.24-4.25, p=0.008) and previous myocardial infarction 
(2.39; 1.31-4.35, p=0.004) remained significant predictors of a major cardiovascular event 
(Figure 14A). 
Figure 12. Time to mortality by strata in Study I. (A) Stratum I: no insulin and low risk (n=272), 
(B) stratum II: no insulin and high risk (n=129), (C) stratum III: insulin and low risk (n=119) and (D) 
stratum IV: insulin and high risk (n=100).
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Table 4. Clinical and laboratory characteristics in patients in Study II by glucose tolerance state.  
The data are presented as n (%) unless otherwise stated.
NGT*
(n=54)
AGT†
(n=113)
p
Clinical characteristics
   Age (years; median (IQR)) 60 (54-67) 65 (57-71) 0.006
   Gender (female) 11 (20) 37 (33) 0.098
   Current smokers 22 (41) 37 (33) 0.312
   BMI (kg/m2; median (IQR)) 26.0 (23.1-28.1) 26.9 (24.1-29.7) 0.074
   Family history of type 2 DM 8 (15) 28 (25) 0.143
   Family history of CHD 30 (57) 60 (54) 0.715
Previous disease 
   Myocardial infarction 7 (13) 25 (22) 0.159
   Angina pectoris 17 (31) 36 (32) 0.961
   Hypertension (treated) 17 (31) 38 (34) 0.783
   Hyperlipidaemia (treated) 8 (15) 19 (17) 0.743
   Heart failure 1 (2) 12 (11) 0.048
   Stroke 1 (2) 5 (4) 0.665
   CABG 3 (6) 11 (10) 0.362
Transmural myocardial infarction 20 (37) 46 (41) 0.620
Reperfusion therapy 33 (61) 48 (42) 0.028
Treatment at discharge
   Aspirin 51 (94) 102 (93) 0.680
   β-blockade 50 (93) 101 (92) 0.863
   ACE inhibitor 9 (17) 16 (15) 0.723
   Statin 38 (86) 49 (62) 0.005
Biochemical variables, admission/day 2 
median (IQR)
   Admission glucose (mmol/L) 5.9 (5.1-7.1) 6.4 (5.8-7.4) 0.002
   HbA1c (%, mmol/mol)‡ 4.8 (4.5-5.1), 
40 (37-43)
5.0 (4.6-5.3), 
42 (38-45)
0.130
   Fasting blood glucose (day 2; mmol/L) 5.2 (4.6-5.7) 5.7 (5.1-6.3) < 0.001
   Creatinine (µmol/L) 92 (85-103) 90 (80-103) 0.517
   Cholesterol (mmol/L) 6.0 (5.3-7.0) 5.9 (5.1-6.7) 0.215
   LDL-cholesterol (mmol/L) 3.8 (3.1-4.4) 3.7 (2.9-4.4) 0.316
   HDL-cholesterol (mmol/L) 1.2 (1.0-1.4) 1.1 (1.0-1.3) 0.304
   Triglycerides (mmol/L) 2.4 (1.5-3.2) 2.1 (1.5-3.0) 0.415
Biochemical variables, day 4-5, median (IQR)
   hs-CRP (mg/L) 13 (6-28) 23 (9-65) 0.003
   Fasting blood glucose (mmol/L) 4.8 (4.5-5.3) 5.3 (4.8-5.7) <0.001
   Two-hour glucose (mmol/L) 6.5 (5.9-7.1) 10.3 (8.8-11.9) <0.001
   Insulin at baseline (pmol/L) 52 (33-68) 56 (37-90) 0.084
   Insulin 30 min (pmol/L) 314 (203-404) 265 (185-400) 0.140
   Insulin 120 min (pmol/L) 240 (132-371) 554 (321-872) <0.001
   IGI§ at discharge 67 (42-98) 45 (27-68) 0.002
   HOMA-IR| |, at discharge (mU mmol/L) 2.05 (1.34-2.64) 2.53 (1.52-3.97) 0.016
IQR=interquartile range. *Normal glucose tolerance. †Abnormal glucose tolerance. ‡HbA1c presented 
as Mono S (%) and IFCC (mmol/mol) standards. §Insulinogenic index. | |HOMA-IR=Homeostasis Model 
Assessment of Insulin Resistance.
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Table 5. Clinical and laboratory characteristics in controls by glucose tolerance state in Study II. 
The data are presented as n (%) unless otherwise stated.
NGT*
(n=119)
AGT†
(n=65)
p 
Clinical characteristics
   Age (years; median (IQR)) 64 (56-71) 67 (60-74) 0.012
   Gender (female) 41 (34) 17 (26) 0.247
   Current smokers 11 (9) 10 (15) 0.211
   BMI (kg/m2; median (IQR)) 25.8 (23.6-28.2) 26.2 (23.4-30.4) 0.359
   Family history of type 2 diabetes 21 (18) 12 (18) 0.911
   Family history of CHD 35 (29) 16 (25) 0.487
Previous disorders
   Hypertension (treated) 14 (12) 19 (29) 0.003
   Hyperlipidaemia (treated) 8 (7) 6 (9) 0.540
Treatment
   Aspirin 8 (7) 10 (15) 0.059
   β-blockade 10 (8) 15 (23) 0.006
   ACE inhibitor 5 (4) 5 (8) 0.318
   Statin 3 (3) 4 (6) 0.246
Biochemical variables, median (IQR)
   HbA1c (% , 
   mmol/mol)‡
4.5 (4.2-4.8), 
37 (33-40)
4.8 (4.4-5.3), 
40 (35-45)
<0.001
   hs-CRP (mg/L) 1.6 (1.0-2.8) 2.1 (0.9-4.8) 0.003
   Creatinine (µmol/L) 80 (71-88) 84 (74-92) 0.034
   Cholesterol (mmol/L) 5.8 (5.3-6.6) 5.6 (5.0-6.1) 0.121
   LDL-cholesterol (mmol/L) 4.1 (3.3-4.6) 3.8 (3.3-4.4) 0.076
   HDL-cholesterol (mmol/L) 1.3 (1.1-1.6) 1.1 (1.0-1.5) 0.071
  Triglycerides (mmol/L) 1.1 (0.9-1.5) 1.3 (1.0-2.0) 0.023
Biochemical variables at OGTT, median (IQR) 
   Fasting blood glucose (mmol/L) 4.8 (4.5-5.2) 5.4 (4.8-5.8) <0.001
   Two-hour glucose (mmol/L) 6.2 (5.5-7.0) 9.1 (8.1-10.9) <0.001
   Insulin at baseline (pmol/L) 45 (31-67) 53 (36-89) 0.118
   Insulin 120 min (pmol/L) 194 (120-293) 349 (224-555) <0.001
   Proinsulin baseline (pmol/L) 2.1 (1.2-4.0) 2.9 (1.7-6.8) 0.013
   HOMA-IR| | at discharge (mU mmol/L) 1.83 (1.28-2.64) 2.38 (1.51-4.11) 0.011
IQR=interquartile range.*Normal glucose tolerance. †Abnormal glucose tolerance. ‡HbA1c presented 
as Mono S (%) and IFCC (mmol/mol) standards. | |HOMA-IR=Homeostasis Model Assessment of 
Insulin Resistance.
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Controls
In controls, AGT was related to a major cardiovascular event (HR 2.13; 95% CI 1.03-4.41, 
p=0.042), while fasting blood glucose (p=0.81) and HbA1c were not (HbA1c ≥4.7%, p=0.77; 
HbA1c 4.7%-5.5%, p=0.70; HbA1c ≥5.6%, p=0.94). Further, univariate variables with a 
p-value of <0.10 are described in Figure 14B. 
The final Cox regression model, including age, gender, hypertension and AGT, identified 
age (1.09; 1.04-1.14, p<0.001), female gender (0.11; 0.03-0.46, p=0.003) and hypertension 
(3.05; 1.36-6.85, p=0.007) as remaining predictors of a major cardiovascular event, while 
AGT did not remain as an independent predictor (Figure 14B).
Study III
Clinical data
Of 58 891 patients, 19% had diabetes, whereof 27% were on diet only and 33% had been 
prescribed oral glucose-lowering drugs and 40% insulin treatment. ACS (unstable angina 
pectoris and AMI) was the most common indication for the PCI. Cardiovascular risk factors, 
multiple coronary vessel disease and left main stem disease were more frequent in patients 
with diabetes, particularly if insulin treated, and their revascularisation was less often 
complete (Table 6). There was no significant difference in the numbers of stents implanted 
in the different groups, although patients with diabetes more frequently received DES than 
those without (33% vs. 24%). Furthermore, there was only a minor difference in pre- and 
per-operative treatment between the two groups.
Cardiovascular events and mortality
In all 1619 (14%) of the patients with diabetes (322 [10.5%] in the diet group, 412 [11%] 
in the oral glucose-lowering group and 885 [19%] in the insulin group) and 3825 (8%) of 
the patients without diabetes died during a mean follow-up period of 920 (SD 530, range 
0-1825) days (estimated cumulative mortality rate presented in Figure 15). 
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Figure 13. Time to major cardiovascular events in patients and controls. Log-rank test p=0.002 for 
patients with AGT vs. NGT. Log-rank test p=0.037 for controls with AGT vs. NGT.
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The composite cardiovascular event (total mortality, AMI, stroke or heart failure) was more 
frequent in patients on insulin followed by those on oral glucose-lowering drugs and diet and 
lowest in patients without diabetes (Figure 16). Following adjustment, the risk of developing 
a composite cardiovascular event was increased in patients on insulin (HR 1.63; 95% CI 
1.55-1.72), on oral treatment (1.23; 1.15-1.31) and on diet only (1.21; 1.12-1.29) compared 
with patients without diabetes. The unadjusted and adjusted risk of a future event is presented 
in Table 7.
The presence of diabetes increased the risk of future non-fatal events, in particular heart 
failure and renal failure. Insulin-treated patients had a substantially increased risk of 
restenosis (1.54; 1.39-1.71) and stent thrombosis (1.56; 1.25-1.96). 
0 1 2 3 4 5 6 7
AGT 2.13; 1.03-4.41, p=0.042 
Hypertension 3.05; 1.36-6.85, p=0.007 
Hypertension 2.68; 1.25-5.77, p=0.012
Age 1.09; 1.04-1.14, p<0.001
Insulin 1.01; 1.00-1.02, p=0.044
Female gender 0.11; 0.03-0.46, p=0.003
Multivariate model (age, gender, hypertension and AGT)
Univariate analyses
Proinsulin 1.07; 1.03-1.12, p<0.001
Female gender 0.14; 0.03-0.61, p=0.008
Insulin at 120 min 1.001; 1.00-1.002, p=0.017
Age 1.09; 1.04-1.14, p<0.001
B. Controls – major cardiovascular event
Previous CHF 3.26; 1.65-6.43, p<0.001 
0 1 2 3 4 5 6 7
BMI 0.94; 0.89-1.00, p=0.033
AGT 2.46; 1.37-4.42, p=0.003
Blood glucose at 120 min 1.09; 1.01-1.17, p=0.027 
AGT 2.30; 1.24-4.25, p=0.008
Previous myocardial infarction 3.43; 2.10-5.59, p<0.001
Previous myocardial infarction 2.39; 1.31-4.35, p=0.004 
Multivariate model 
(AGT, age, BMI, previous angina pectoris/myocardial infarction/CHF/CABG) 
Univariate analyses 
Previous angina pectoris 2.08; 1.30-3.32, p=0.002
HOMA-IR discharge 1.07; 0.99-1.15, p=0.099
Previous CABG 3.21; 1.68-6.15, p<0.001 
Age 1.04; 1.02-1.07, p=0.003
A. Patients- major cardiovascular event
Figure 14. Variables related to major cardiovascular events in patients (A) and controls (B) in 
univariate and multivariate analyses.
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Table 6. Baseline characteristics by diabetes status and treatment at first PCI. The data are 
presented as n (%) unless otherwise stated.
No diabetes 
n=47454 
n (%)
Diabetes  
n=11437 
n (%)
Diet 
n=3061 
n (%)
Oral 
n=3771 
n (%)
Insulin 
n=4605 
n (%)
P 
overall
Clinical characteristics
   Age; years, mean (SD) 66          (11) 68         (11) 67       (11) 68         (10) 67        (11) <0.001
   Male 33816   (71) 7639     (67) 2122   (69) 2626     (70) 2891    (63) <0.001
   Smoker (yes) 11158   (24) 2160     (19) 725     (24) 683       (18) 752      (16) <0.001
Previous diseases
   Hypertension (treated) 20468   (43) 7744     (68) 1777   (58) 2671     (71) 3296    (72) <0.001
Hyperlipidaemia (treated) 15847   (33) 6275     (55) 1258   (41) 2130     (57) 2887    (63) <0.001
   Myocardial infarction 4456     (9) 1906     (17) 382     (13) 573       (15) 951      (21) <0.001
   Heart failure 1708     (4) 1006     (9) 176     (6) 232       (6) 598      (13) <0.001
   Stroke 2367     (5) 1073     (9) 197     (6) 321       (9) 555      (12) <0.001
   Renal insufficiency 472       (1) 392       (3)  69      (2) 34         (1) 289      (6) <0.001
   Peripheral artery disease 1105     (2) 356       (3) 100     (3) 123       (3) 333      (7) <0.001
Indication for PCI  
   Stable CAD disease 7460     (16) 2107     (18) 402     (13)  791      (21) 914      (20) <0.001
   Non-ST-elevation ACS* 22333   (47) 5675     (50) 1460   (48) 1855     (49) 2360    (51) <0.001
   STEMI 16633   (35) 3383     (30) 1150   (38) 1034     (27) 1199    (26) <0.001
PCI result
   Complete      
   revascularisation 30288   (64) 6388     (56) 1799   (59) 2163     (57) 2426    (53) <0.001
Angiographic finding
   Normal/atheromatosis 588        (1) 152       (1) 46       (2) 48        (1) 58        (1) <0.001
   One-vessel disease 24679   (52) 4853     (42) 1423   (47) 1638    (43) 1792    (39) <0.001
   Two-vessel disease 14273   (30) 3728     (33)  949    (31) 1262    (34) 1517    (33) <0.001
   Three-vessel disease 6520     (14) 2260     (20)  531    (17) 704      (19) 1025    (22) <0.001
   Left main stem disease 1345     (3) 419       (4)  107    (4) 108      (3)  204      (4) <0.001
Stent implantation
   Stents/patient; mean (SD) 1.5        (0.9) 1.5       (1.0) 1.5     (0.9) 1.5       (0.9) 1.5      (1.0) 0.441
   Drug-eluting stent (%) 11545  (24) 3802     (33) 823    (27) 1279    (34) 1700    (37) <0.001
   Only bare metal stent (%) 32937  (69) 6677     (58) 2022  (66) 2194    (58) 2461    (53) <0.001
   No stent (%) 2972    (6) 742       (7) 216    (7) 298      (8) 444      (10) <0.001
Treatment at PCI
   Aspirin (before) 43257   (91) 10521   (92) 2807   (92) 3492    (93) 4222    (92) 0.059
   Clopidogrel (before) 38768   (82)   9291   (81) 2528   (83) 3081    (82) 3682    (80) 0.042
   Bivalirudin  (during) 10093   (21)   2355   (21) 635     (21) 785      (21) 935      (20) <0.001
   GP2B/3A inhibitor (during) 12531   (26)   2721   (24) 891     (29) 835      (22) 995      (22) <0.001
* Non-ST-elevation ACS: unstable angina or non-ST-elevation myocardial infarction.
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Figure 15. Estimated cumulative rate of mortality after a first PCI in patients with and without 
diabetes and by glucose treatment. 
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Figure 16. Estimated cumulative rate of the composite endpoint (total mortality, AMI, stroke or heart 
failure) after a first PCI in patients with and without diabetes and by glucose treatment. 
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Table 7. Unadjusted and adjusted risk of a first event after PCI in patients with diabetes by glucose-
lowering treatment in comparison with patients without diabetes.
Event Unadjusted
HR (95% CI)
p Adjusted†
HR (95% CI)
p
All-cause mortality
    No diabetes 1 1
    Diet 1.30 (1.16-1.46) <0.001 1.22 (1.09-1.37) <0.001
    Oral 1.40 (1.26-1.55) <0.001 1.22 (1.10-1.35) <0.001
    Insulin 2.59 (2.41-2.79) <0.001 1.91 (1.77-2.07) <0.001
AMI
    No diabetes 1 1
    Diet 1.23 (1.11-1.37) <0.001 1.11 (0.99-1.23) 0.064
    Oral 1.17 (1.06-1.29) 0.002 1.09 (0.98-1.20) 0.108
    Insulin 1.69 (1.57-1.83) <0.001 1.40 (1.29-1.53) <0.001
Heart failure
    No diabetes 1 1
    Diet 1.65 (1.49-1.82) <0.001 1.47 (1.33-1.63) <0.001
    Oral 1.63 (1.49-1.79) <0.001 1.41 (1.28-1.55) <0.001
    Insulin 2.64 (2.45-2.83) <0.001 1.90 (1.76-2.05) <0.001
Stroke
    No diabetes 1 1
    Diet 1.45 (1.19-1.75) <0.001 1.33 (1.09-1.61) 0.004
    Oral 1.65 (1.40-1.95) <0.001 1.38 (1.16-1.64) <0.001
    Insulin 2.02 (1.74-2.33) <0.001 1.54 (1.33-1.80) <0.001
Renal failure
    No diabetes 1 1
    Diet 2.07 (1.72-2.48) <0.001 1.67 (1.39-2.00) <0.001
    Oral 1.82 (1.52-2.18) <0.001 1.47 (1.23-1.77) <0.001
    Insulin 5.15 (4.60-5.77) <0.001 2.70 (2.38-3.06) <0.001
Restenosis
    No diabetes 1 1
    Diet 1.09 (0.95-1.25) 0.232 1.07 (0.93-1.23) 0.320
    Oral 1.16 (1.03-1.31) 0.016 1.16 (1.03-1.31) 0.019
    Insulin 1.64 (1.48-1.81) <0.001 1.54 (1.39-1.71) <0.001
Stent thrombosis
    No diabetes 1 1
    Diet 1.01 (0.74-1.38) 0.943 1.01 (0.74-1.38) 0.934
    Oral 0.97 (0.73-1.30) 0.849 1.00 (0.75-1.34) 0.983
    Insulin 1.66 (1.34-2.06) <0.001 1.56 (1.25-1.96) <0.001
CABG
    No diabetes 1 1
    Diet 1.11 (0.90-1.37) 0.331 0.98 (0.79-1.21) 0.834
    Oral 1.49 (1.26-1.77) <0.001 1.37 (1.16-1.63) <0.001
    Insulin 1.44 (1.23-1.69) <0.001 1.26 (1.07-1.49) 0.006
Re-PCI
    No diabetes 1 1
    Diet 1.16 (1.06-1.27) 0.001 1.09 (0.99-1.20) 0.067
    Oral 1.14 (1.04-1.24) 0.003 1.05 (0.96-1.14) 0.295
    Insulin 1.29 (1.20-1.39) <0.001 1.10 (1.02-1.19) 0.014
Combined cardiovascular event 
(mortality/AMI/stroke/HF*)
    No diabetes 1 1
    Diet 1.32 (1.23-1.41) <0.001 1.21 (1.12-1.29) <0.001
    Oral 1.36 (1.28-1.45) <0.001 1.23 (1.15-1.31) <0.001
    Insulin 2.05 (1.95-2.16) <0.001 1.63 (1.55-1.72) <0.001
*Heart failure (HF). †Adjusted for age, indication, gender, hospital, admission year, previous myocardial infarction, 
previous heart failure, previous renal insufficiency, previous stroke, hypertension, hyperlipidaemia, dementia, cancer 
diagnosis within three years, dialysis, chronic obstructive pulmonary disease, peripheral artery disease, smoking, 
angiographic findings, complete revascularisation, treated stenosis at bifurcation, treated chronic occlusion, BMS, 
DES or balloon, numbers of stents, aspirin, clopidogrel or warfarin before PCI, GP2B3A-inhibitor, heparin or bivalirudin 
treatment during PCI.
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Study IV
Clinical data related to adiponectin 
The median level of adiponectin on day 2 was 10.2 mg/L for men (IQR 6.7-14.5) and 16.6 
mg/L (IQR 12.2-24.1) for women and at discharge 8.6 mg/L (IQR 5.9-14.4) for men and 
16.3 mg/L (IQR 10.2-21.7) for women. The clinical and laboratory characteristics of patients 
above and below the median level of adiponectin at discharge are presented in Table 8. 
Patients with adiponectin levels above median were older, with a lower BMI and HOMA 
index and had a more frequent history of heart failure. The cut-off level for the highest 
quartile of adiponectin at discharge was 14.4 mg/L in men and 21.7 mg/L in women.
Adiponectin and mortality risk
During a median follow-up period of 11.6 years (IQR 9.6-12.1), 34% (n=61) of the patients 
died and 80 (44%) experienced a major cardiovascular event. Patients that died showed 
increasing levels of adiponectin during hospitalisation (median 0.2 mg/L (IQR -2.7 to 
2.7), compared with survivors whose levels were decreasing (-0.2, -3.6 to 0.5; p=0.011). 
Adiponectin levels above the median at discharge were associated with higher mortality 
(p<0.001; Figure 17), with gradually separating curves over time, while the rate of major 
cardiovascular events did not differ between those above/below the median levels of 
adiponectin (log-rank p=0.234).
After adjustments for age, adiponectin levels on day 2 did not predict mortality or major 
cardiovascular events, while high adiponectin levels at discharge remained a predictor of total 
mortality (1.69; 1.07-2.68, p=0.026) and cancer mortality (3.87; 1.43-10.48, p=0.008). After 
further adjustment for previous myocardial infarction, previous CHF and BMI, adiponectin 
still predicted total mortality (1.67; 1.04-2.68, p=0.035) and remained even when gender 
was forced into the model (1.79; 1.07-3.00, p=0.027). When adiponectin was categorised 
as gender-specific median values, it did not substantially change the predictive value (data 
not shown). High levels of adiponectin at discharge corresponding to the highest quartile 
(men: >14.4 mg/L; women: >21.7 mg/L) were strongly associated (age adjusted) with total 
mortality (3.57; 1.30-9.82, p=0.014). Mortality by quartiles of adiponectin at discharge is 
presented in Figure 18.  
Clinical data related to leptin
The median level of leptin was 8.9 ng/ml for men and 22.6 ng/ml for women on day 2 
and 6.7 ng/L for men and 22.2 ng/ml for women at discharge. The clinical and laboratory 
characteristics of patients by the median level of leptin on day 2 are presented in Table 9. 
Patients with leptin levels above median had a higher BMI, HOMA-IR, CRP, triglycerides 
and more frequent AGT and previous hypertension but a less frequent history of cancer. 
Leptin and cardiovascular risk
Leptin levels on day 2 or at discharge with or without categorisation by gender-specific 
medians did not predict total mortality or any major cardiovascular events during the 
complete follow-up period. Leptin levels above the median on day 2 did however predict 
major cardiovascular events during the first seven years following the index AMI (unadjusted 
HR; 95% CI by year: 1: 1.70; 1.10-2.63, year 2: 1.70; 1.15-2.53, year 3: 1.55; 1.06-2.28, year 
4: 1.57; 1.09-2.26, year 5: 1.52; 1.07-2.15, year 6: 1.48; 1.05-2.07, year 7: 1.39; 1.01-1.91), 
as illustrated by the converging Kaplan-Meier curves (Figure 19).
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Table 8. Clinical and laboratory characteristics in patients divided into those above and below the 
median (men 8.6 mg/L, women 16.3 mg/L) for adiponectin at discharge. The data presented are n 
(%) unless otherwise stated.
Adiponectin
≤median (n=81)
Adiponectin
>median (n=81)
p
n (%) or median (IQR) n (%) or median (IQR)
Clinical characteristics
  Age (years), median (IQR) 60 (54-67) 67 (60-74) <0.001
  Gender (male) 57 (70) 57(70) 1.000
  Current smoker 33 (41) 24 (30) 0.139
  BMI (kg/m2), median (IQR) 28.2 (25.2-30.4) 24.6 (22.3-26.8) <0.001
Blood pressure (mm/Hg), median (IQR)
  Systolic 156 (133-177) 146 (135-160) 0.073
  Diastolic 94 (83-105) 90 (80-100) 0.195
Medication prior to admission
  Aspirin 23 (28) 47 (58) 0.594
  β-blockade 26 (32) 28 (35) 0.739
  ACE inhibitor 8 (10) 7 (9) 0.786
  Statin 10 (12) 9 (11) 0.807
Transmural myocardial infarction 35 (43) 28 (35) 0.509
Reperfusion therapy 41 (51) 39 (48) 0.694
Medication at discharge
  Aspirin 73 (90) 75 (93) 0.738
  β-blockade 75 (93) 70 (86) 0.098
  ACE inhibitor 9 (11) 15 (19) 0.195
  Statin 47 (58) 40 (49) 0.204
Previous disease
 Myocardial infarction 16 (20) 15 (19) 0.842
 Heart failure 3 (4) 10 (12) 0.043
 Hypertension 29 (36) 23 (28) 0.313
 Hyperlipidaemia 16 (20) 9 (11) 0.128
 Stroke 3 (4) 3 (4) 1.000
 Cancer 1 (1) 3 (4) 0.620
Biochemistry, median (IQR) or n (%)
  Fasting blood glucose (mmol/L) day 2 5.6 (5.0-6.1) 5.4 (4.8-6.1) 0.365
  HbA1c (%), (mmol/mol)* day 2 4.9 (4.5-5.3), 41 (36-45) 4.9 (4.6-5.2), 41 (37-44) 0.928
  Creatinine (mmol/L) at admission 92 (81-102) 89 (82-103) 0.902
  hs-CRP day 2 (mg/L) 11 (4-26) 12 (5-25) 0.657
  Cortisol day 2 (nmol/L) 442 (342-574) 489 (347-586) 0.363
  Cholesterol day 2 (mmol/L) 6.0 (5.2-7.2) 5.9 (5.1-6.6) 0.150
  LDL day 2 (mmol/L) 3.7 (3.1-4.6) 3.9 (3.1-4.4) 0.694
  HDL day 2 (mmol/L) 1.1 (0.9-1.3) 1.2 (1.1-1.4) <0.001
  Triglycerides day 2 (mmol/L) 2.6 (1.8-3.2) 1.7 (1.4-2.4) <0.001
  Abnormal glucose tolerance at OGTT 55 (68) 51 (63) 0.737
  IGI† at discharge 49 (33-80) 50 (26-87) 0.906
  HOMA-IR‡ at discharge (mU mmol/L) 2.73 (1.69-4.20) 1.93 (1.20-2.67) <0.001
  Leptin at discharge (ng/ml) 11.4 (7.0-20.7) 6.4 (4.2-15.2) 0.003
IQR=interquartile range. *HbA1c presented as Mono S standard (%) and IFCC (mmol/mol). †IGI=Insulinogenic 
Index. ‡HOMA-IR=Homeostasis Model Assessment of Insulin Resistance.
          Glucose abnormalities and cardiovascular disease
43
Figure 17. Kaplan-Meier curves for adiponectin at discharge divided into patients above and below 
the median (men 8.6 mg/L), women 16.3 mg/L) related to all-cause mortality, log-rank (p<0.001).
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Figure 18. Mortality percentages (%) by quartiles of adiponectin at discharge.
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Table 9. Clinical and laboratory characteristics of patients divided into those above and below the 
median (men 8.9 ng/ml and women 22.6 ng/ml) for leptin on day 2. The data presented are n (%) 
unless otherwise stated.
Leptin
≤median (n=91)
Leptin
>median (n=89) p
n (%) or median (IQR) n (%) or median (IQR)
Clinical characteristics
  Age (years), median (IQR) 62 (56-70) 64 (57-72) 0.130
  Male gender 28 (31) 28 (31) 0.920
  Current smoker 36 (40) 25 (28) 0.243
  BMI (kg/m2), median (IQR) 24.1 (22.3-26.2) 28.6 (26.0-31.1) <0.001
Blood pressure (mm/Hg), median (IQR)
  Systolic 150 (130-170) 150 (133-172) 0.391
  Diastolic 90 (80-101) 93 (80-100) 0.629
Medication prior to admission
  Aspirin 22 (24) 29 (33) 0.211
  β-blockade 26 (29) 32 (36) 0.289
  ACE inhibitor 6 (7) 10 (11) 0.274
  Statin 9 (10) 11 (12) 0.598
Transmural myocardial infarction 34 (37) 35 (39) 0.761
Reperfusion therapy 51 (56) 35 (39) 0.029
Medication at discharge
  Aspirin 83 (92) 77 (93) 0.891
  β-blockade 79 (88) 79 (95) 0.084
  ACE inhibitor 12 (13) 14 (17) 0.516
  Statin 52 (76) 41 (66) 0.192
Previous disease
 Myocardial infarction 14 (15) 22 (25) 0.118
 Heart failure 8 (9) 6 (7) 0.608
 Hypertension 19 (21) 38 (43) 0.002
 Hyperlipidaemia 12 (13) 15 (17) 0.491
 Stroke 2 (2) 4 (4) 0.441
 Cancer 5 (5) 0 (0) 0.059
Biochemistry, median (IQR) or n (%)
  Fasting blood glucose (mmol/L) day 2 5.3 (4.8-5.8) 5.7 (5.2-6.7) <0.001
  HbA1c (%), 
  (mmol/mol)* day 2
4.9 (4.6-5.2), 
41 (37-44)
5.0 (4.5-5.4), 
42 (36-46)
0.414
  Creatinine (mmol/L) at admission 89 (81-101) 94 (81-106) 0.263
  hs-CRP day 2 (mg/L) 10.0 (3.6-18.2) 14.9 (5.7-38.6) 0.032
  Cortisol day 2 (nmol/L) 487 (353-617) 463 (334-584) 0.395
  Cholesterol day 2 (mmol/L) 6.0 (5.2-6.7) 6.0 (5.2-7.4) 0.317
  LDL day 2 (mmol/L) 3.9 (3.1-4.4) 3.7 (3.0-4.7) 0.038
  HDL day 2 (mmol/L) 1.1 (1.0-1.3) 1.1 (1.0-1.3) 0.735
  Triglycerides day 2 (mmol/L) 1.95 (1.40-2.85) 2.50 (1.75-3.30) 0.004
  Adiponectin day 2 (mg/L) 13.5 (9.4-20.9) 10.9 (6.8-15.1) 0.002
  Abnormal glucose tolerance at OGTT 47 (56) 66 (80) 0.001
  IGI† at discharge 47 (27-70) 50 (35-83) 0.217
  HOMA-IR‡ at discharge (mU mmol/L) 1.78 (1.17-2.44) 3.00 (2.19-4.57) <0.001
IQR=interquartile range. *HbA1c presented as Mono S standard (%) and IFCC (mmol/mol). †IGI=Insulinogenic 
Index. ‡HOMA=Homeostasis Model Assessment of Insulin Resistance.
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Table 10. Events in the GAMI cohort during follow-up (patients 11.6 years and controls 10.4 years).
All patients 
n=180
n (%)
Patients with 
NGT
n=54
n (%)
Patients 
with AGT
n=113
n (%)
Patients with 
adiponectin 
≤median
n=81
n (%)
Patients with 
adiponectin 
>median
n=81
n (%)
All controls
n=184
n (%)
Controls 
with NGT
n=119
n (%)
Controls 
with AGT
n=65
n (%)
Total mortality 61 (34) 14 (26) 39 (35) 15 (19) 36 (44) 28 (15) 13 (11) 15 (23)
        Cardiovascular     
        death
35 (19) 5 (9) 26 (23) 10 (67) 21 (58) 12 (7) 4 (3) 8 (12)
        Cancer death 18 (10) 9 (17) 6 (5) 4 (27) 10 (28) 11 (6) 7 (6) 4 (6)
        Miscellaneous   
        death* 7 (4) 0 (0) 6 (5) 1 (7) 5 (14) 5 (3) 2 (2) 3 (5)
Non-fatal stroke 15 (8) 3 (6) 11 (10) 7 (9) 7 (9) 7 (4) 3 (3) 4 (6)
Non-fatal 
myocardial 
infarction
34 (19) 5 (9) 26 (23) 16 (20) 14 (17) 10 (5) 6 (5) 4 (6)
Severe heart failure 23 (13) 3 (6) 20 (18) 6 (7) 17 (21) 6 (3) 4 (3) 2 (3)
Major 
cardiovascular 
event
80 (44) 14 (26) 58 (49) 31 (38) 40 (49) 29 (16) 14 (12) 15 (23)
*Death due to infections, accidents etc. One patient could not be classified according to death cause. Each event 
is recorded only once.
Studies II and IV
Outcome
Overview for events and patients and controls in the GAMI cohort by glucose tolerance state 
and medians of adiponectin and leptin (Table 10).
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Figure 19. Kaplan-Meier curves for leptin on day 2 divided into patients above and below the median 
(men 8.9 ng/ml; women 22.6 ng/ml) related to cardiovascular events (log-rank p=0.422).
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Table 11. Mortality causes (%) by study cohort. Data presented are the proportion of  the total 
mortality within each cohort.
DIGAMI (I) GAMI (II, IV) SCAAR (III)
Intensified Control Patients Controls No Diabetes Diabetes
Cardiovascular 79 81 57 43 67 64
   Ischaemic 48 43 41 18 56 54
   Heart failure 7 9 10 7 2 2
   Cerebrovascular 5 12 2 4 6 5
Cancer 8 7 30 39 18 12
Other 13 12 11 18 15 24
Other=infection, renal disease, respiratory disease, gastrointestinal disease or endocrine/metabolic disease.
Studies I-IV
Mortality causes
Mortality causes in the three different study populations are presented in Table 11. 
Cardiovascular reasons were behind 80% of the mortality causes in the patients with diabetes 
and myocardial infarction in the DIGAMI cohort and 64% among individuals with diabetes 
compared with 67% without diabetes in the SCAAR cohort. There were no major differences 
in mortality causes between the intensified and the control group in Study I (DIGAMI). In 
the GAMI cohort (Studies II and IV) cardiovascular death was more common in patients and 
cancer was more frequent in controls. In Study III (SCAAR) death due to cancer was more 
common among patients without diabetes while endocrine/metabolic diseases were a more 
prevalent cause of death in patients with diabetes. 
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GENERAL  DISCUSSION
Diabetes and previously undetected glucose abnormalities are common in patients with 
AMI and affect the subsequent prognosis. Despite improvements in the management of 
acute coronary events during the last decades patients with diabetes are still at increased 
risk in terms of mortality and new cardiovascular events. The focus of the present thesis is 
to characterise patterns of complications, mortality causes and the impact of glucose control 
after AMI with the aim to identify potential ways to improve the prognosis. Both patients 
with established diabetes and newly detected glucose abnormalities were studied.
Glucose control and cardiovascular outcome
Both an extensive use of evidence based therapy in the acute setting and a carefully 
conducted secondary prevention are important to improve the prognosis after AMI in patients 
with diabetes.204 In addition primary prevention and multifactorial risk factor control are 
of importance to reduce cardiovascular complications.215-218 The UKPDS found that LDL, 
blood pressure and HbA1c were the strongest predictors for CHD in patients with type 2 
diabetes at low cardiovascular risk.215-217 The Steno-2 study underlined the importance of a 
multifactorial intervention to reduce mortality and decrease micro- as well as  macrovascular 
complications in patients with type 2 diabetes and microalbuminuria.218 The investigators 
behind the Steno 2 study analysed the relative contribution of lipid, blood pressure and 
glucose control to the observed cardiovascular benefits. They noted that lipid control (73% of 
the benefit) was considerably more important than blood pressure (11%) and glucose control 
(13%).219 The capability of glucose control to reduce macrovascular complications has after 
the DIGAMI 2, ACCORD, ADVANCE and Veteran’s Affairs Diabetes Trial (VADT) studies 
been questioned, especially in patients with longstanding diabetes and established CVD. One 
exception is the use of metformin, which reduced total mortality and myocardial infarction 
in overweight newly diagnosed diabetes patients in the UKPDS study and the major reason 
behind the recommendations of metformin as first-line therapy.174 
Study I demonstrates that intensified, insulin-based glycaemic control in patients with 
AMI and clearly deranged blood glucose is of importance, increasing longevity by almost 
50%.220 These results from a cohort with established CAD extends the results from primary 
prevention as in the long-term follow-up of DCCT and UKPDS.140,221 In these studies the 
positive impact of intensified glycaemic control on mortality and macrovascular events was 
not noted until 22 and 30 years of follow-up respectively while the impact on microvascular 
complications was seen already earlier. The benefit was seen despite a convergence of HbA1c 
levels over time giving rise to the discussion of a glycaemic memory, “the legacy effect”, first 
in type 1 diabetes (DCCT) and thereafter in type 2 diabetes (UKPDS).140,221 The background 
for this legacy effect has been debated and it has been proposed that it does not only apply 
to improved glucose levels but also to control of other vascular risk factors as blood lipids222 
and hypertension.223,224 Mechanisms for the glycaemic memory may include formation of 
superoxide anions,225 reduced NO availability,226 changes in glycation which may alter 
the function of proteins,227 and activation of NFkB pathway mediating inflammation.226 
Furthermore gene expression may be modified through changes in microRNA228 and epigenetic 
changes where the up-regulation of Pin1 has been suggested crucial.226 As the legacy effect 
Viveca Ritsinger
48
comprises factors that are important during a lifetime, affecting on outcome seen later in life, 
it highlights the importance of early instituted glucose- and risk factor control. Moreover 
it underlines the relevance of long-term follow-up of trials studying such interventions as 
in the 20 years report of the first DIGAMI cohort, which followed patients towards 90% 
mortality. A too short study period may explain why the ACCORD170 study, terminated 
prematurely after 3.5 years because of a rising mortality rate in the intensified group, or 
ADVANCE169 with 5 years of follow-up was not able to show any cardiovascular benefit 
despite high event rates. Compared to DCCT127 and UKPDS,128 ACCORD,170 ADVANCE169 
and VADT173 included patients at high cardiovascular risk. In Study I intensified insulin-based 
glycaemic control had the most pronounced effect in patients with low cardiovascular risk 
without previous insulin treatment while it did not seem to improve the outcome in patients 
at high risk without previous insulin. This supports the conclusions from the ACCORD and 
ADVANCE trials that intensified glycaemic control in patients with longstanding diabetes 
and advanced CVD does not seem to improve mortality. There are several explanations to 
the discrepant findings in Study I compared to the ACCORD and ADVANCE trials. It must 
be kept in mind that in the DIGAMI cohort (Study I) secondary prevention was considerably 
less well developed compared to such studies as ACCORD and ADVANCE, for instance, 
angiotensin-converting enzyme inhibitors were only prescribed to a third of the patients and 
none received statins as the integration of statins in secondary prevention was started after 
1994.229 Moreover glycaemic control at hospital admission was considerably worse and the 
subsequent mortality higher when Study I was conducted compared to the conditions when 
the more recent studies were initiated. The proportionate impact of the intensified glycaemic 
control might therefore have been much more apparent. 
It has been debated which glycaemic level to aim for and likewise what choice of glucose 
lowering therapy that is most beneficial. The intensified insulin-based treatment in DIGAMI, 
aimed for a blood glucose of 7-10 mmol/L during the period of intensive care and a fasting 
level <7 mmol/L during follow-up. In ACCORD the intensified target, an HbA1c <6.0% 
(IFCC <42 mmol/mol), was lower than in previous studies while the standard target was 
an HbA1c of 7.0-7.9% (IFCC 53-63 mmol/mol). To reach these goals several glucose 
lowering drugs were allowed introducing a potential for complex drug interactions and risk 
for hypoglycaemia. For instance 91% in the intensified group vs. 58% in the standard group 
were treated with rosiglitazone, a drug that was withdrawn from the market in 2010 due to 
a suspicion of increased cardiovascular risk.170 In ADVANCE all patients in the intensified 
group were treated with sulphonylurea among other glucose lowering therapy to achieve 
HbA1c ≤6.5 (IFCC ≤48 mmol/mol) with potential increased risks for hypoglycaemia.169 In 
DIGAMI 10% of the patients in the intensified group had to stop insulin treatment during 
hospitalisation because of hypoglycaemic episodes. In ACCORD, ADVANCE and VADT 
hypoglycaemia was at least twice as common in the intensive compared to the control arm 
(intensive vs. standard group; 10.5 vs. 3.5, 2.7 vs. 1.5 and 21.2 vs. 9.9%).169,170,173 However, 
although an association of hypoglycaemia and increased cardiovascular mortality risk has 
been described, it is not clearly established that pharmacologically induced hypoglycaemic 
episodes are related to increased cardiovascular risk and if this may have contributed to 
the increased mortality in the ACCORD study.230,231 Both in the NICE-SUGAR232 and in the 
ORIGIN study233 there was a stronger association between hypoglycaemia and cardiovascular 
mortality in the control than in the insulin arm respectively. If there is a causality link between 
hypoglycaemia and adverse events or if a hypoglycaemic event identifies patients that are 
vulnerable due to other reasons is not fully elucidated as mortality from other causes than 
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cardiovascular are dominant the following year after a severe hypoglycaemia.234
Study I is not able to answer whether the gain in life expectancy relates to the initial glucose 
insulin infusion or the continued long-term glucose control. DIGAMI 2171 was designed to 
clarify this but did not show any mortality benefit during the period of hospitalisation or the 
three years of follow-up. In fact the first DIGAMI study is the only study that have showed 
reduced mortality with intensified glucose control after AMI.171 One reason for this may be 
that no significant difference in glucose levels between the intensified insulin-based and the 
control group was achieved in DIGAMI 2. Another explanation is that blood glucose and 
HbA1c at admission were substantially higher in DIGAMI 1 than DIGAMI 2 (mean blood 
glucose 15.4 mmol/L ±SD 4.1 vs. 12.8 mmol/L ±SD 4.5 and HbA1c 8.2% ±SD 1.9 vs. 7.2% 
±SD 1.7).171
In summary there are five major reasons why only the first DIGAMI study and few other 
studies succeed to show benefits of intensive glucose lowering on cardiovascular outcome. 
First, inclusion of high-risk patients with long-standing type 2 diabetes and increased 
incidence of advanced vascular damage with less possibilities to influence already existing 
damage.235 Secondly extensive use of concomitant treatment of other cardiovascular risk 
factors.235 Third, aggressive glucose lowering therapy may be associated with risk of 
hypoglycaemia and weight gain but also direct harmful drug interactions.128,235,236 Fourth, 
as in DIGAMI 2, that no significant difference was achieved in glucose control between 
the intensive and standard arm.171,235 Finally it should be considered if the most appropriate 
outcome was studied. Currently the most common initial manifestation of macrovascular 
disease in patients with diabetes include peripheral arterial disease and heart failure while 
cardiovascular mortality and the incidence of AMI and stroke has declined.139,237 These 
endpoints may have made sense when the UKPDS and the first DIGAMI trials were initiated 
but perhaps not in the contemporary environment. Still most clinical trials continued to use 
a composite of cardiovascular mortality, non-fatal AMI or stroke as the primary outcome. As 
demonstrated in Study III heart failure was the most common adverse event (19%) among 
patients with diabetes treated with a first PCI.238 Hospitalisation for heart failure might thus 
be a previous neglected but a more appropriate primary outcome to address when studying 
cardiovascular morbidity in patients with diabetes.239 Furthermore, other approaches than 
tight glucose control to reduce cardiovascular complications might be beneficial although 
studied in a limited extent. In this respect the recent EMPA-REG OUTCOME study, the 
LEADER trial and the SUSTAIN-6 trial are of interest. There was a statistically significant 
reduction of cardiovascular and total mortality as well as for hospitalisation for heart failure 
(35%) in the EMPA-REG OUTCOME study177 and cardiovascular and total mortality in the 
LEADER trial178 when adding the SGLT-2-inbhibitor empagliflozin177 or the GLP-1 receptor 
agonist liraglutid178 to standard therapy in patients with type 2 diabetes. In SUSTAIN-6 
the rate of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke was 
significantly lower among patients receiving the long-acting GLP-1 receptor agonist 
semaglutide compared to those receiving placebo, principally driven by a significant (39%) 
decrease in the rate of non-fatal stroke.179 Only modest improvements in glycaemic control 
were detected in these trials why other mechanisms than strict glucose lowering seem to be 
crucial to improve outcome.
 
Long-term outcome after coronary artery disease and revascularisation
Multifactorial treatment in patients with diabetes and coronary heart disease also comprises 
interventional therapy as PCI and CABG if signs of coronary ischaemia.240 In a modern 
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unselected nationwide cohort as the SCAAR population in Study III a significant proportion 
of patients with diabetes are naive to coronary interventions despite suffering a previous 
AMI (17% compared to 9% in patients without diabetes). This indicates an underuse of 
revascularisation especially among patients with diabetes. For patients with diabetes and 
multivessel disease CABG has been documented as a better revascularisation alternative than 
PCI due to lower mortality and less coronary events during follow-up.205-207 Still 15% (20% 
of those with diabetes vs. 14% of those without) of the patients in Study III undergoing a first 
PCI have three-vessel disease. It can only be speculative if those patients rather should have 
been subjected to a CABG rather than a PCI and if that would have altered their prognosis. 
Furthermore the decision might have been influenced by the patient preference and/or the 
doctor’s recommendation to avoid open surgery due to comorbidities. Patients treated with 
insulin are at a particularly high risk including stent occlusions and restenosis. In Study 
III 45% of insulin treated patients had a new cardiovascular event (total mortality, stroke, 
myocardial infarction and heart failure) within three years. The strikingly high event rate in 
a modern setting advocates a close follow-up of patients with diabetes in order to reduce the 
complication rate. The event rate from this unselected cohort is higher than in the randomised 
controlled Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal 
Management of Multivessel Disease (FREEDOM) trial in which the subgroup on insulin 
had a five-year event rate (all-cause mortality, stroke, myocardial infarction) of 32% 
after PCI.241 In this context it is of interest that the event rate was significantly reduced, 
regardless of insulin or coronary lesion complexity (estimated as SYNTAX score) in patients 
randomised to CABG.241 Unfortunately the assessment of SYNTAX score was not feasible 
in Study III, but such information could have given further details on the complexity of 
the CAD in individuals with diabetes with or without insulin treatment and its eventual 
influence on outcome. Reasons why the insulin treated patients are especially prone to future 
cardiovascular event cannot be explained in Study III but only be speculative since treatment 
was not randomised. The increased proportion of restenosis and stent occlusions can only 
explain some events. Prescription of insulin can reasonably be considered as a proxy for 
long standing diabetes where the insulin treated group may reflect a more severe disease that 
may not be possible to adjust for. The results from Study I and from the ORIGIN study, the 
first with reduced mortality with insulin-based glucose control and the latter with a neutral 
effect on cardiovascular outcome in the insulin group, contradicts that insulin per se should 
be harmful compared to the standard therapies available at that time.220,242   
Impact of undetected glucose abnormalities on long-term outcome
Around twenty per cent of the patients suffering from an AMI have previously known 
diabetes,155 another  two thirds have unknown glucose abnormalities which can be identified 
by an OGTT.156 Several investigations studied the prognostic implication of newly detected 
glucose abnormalities in a short-term perspective up to three years following an AMI.160-163 
However the long-term follow-up of the GAMI cohort (Study II) reveals that newly detected 
AGT constitute an important, independent and long-lasting prognostic factor during at least 
a decade after an AMI.243 Neither fasting glucose nor HbA1c had the predictive power as 
categorisation of AGT from 2-hour post load glucose levels.243 Our findings contrasts those 
presented by Kuhl et al. They studied 750 patients with ACS from a single Swedish center 
during four years without finding any difference in terms of mortality and re-infarction between 
those with NGT and AGT.244 This discrepancy is confusing but an explanation might be a 
difference in the methodological follow-up of the OGTT results. Kuhl et al. communicated 
the result of the OGTT to the patients and glucose lowering treatment was initiated if diabetes 
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was detected which might have influenced long-term outcome.244 George et al. did on the 
other hand present results similar to those in the GAMI study and demonstrated that IGT and 
newly detected diabetes in patients with AMI were independently associated with an increase 
in cardiovascular events and mortality two years after an AMI.245 This was found despite 
advisements of lifestyle modifications and referral to a diabetologist.245 However there was 
no data on type of glucose lowering treatment or adherence to such lifestyle modifications. 
In the GAMI cohort (Study II) patients were referred to their ordinary physician for further 
management if the OGTT at three months indicated diabetes. None of the patients received 
information on the OGTT results at discharge.
It has been debated if and how to best screen for dysglycaemia. The WHO criteria for an 
appropriate screening test were first published by Wilson and Jungner in 1968246 and further 
modified in 2008 by Andermann et al.247 The criteria include a recognised need of screening 
with a target population, a predefined objective and a scientific evidence of effectiveness.246,247 
In addition the overall benefits of screening should outweigh the potential harm. An OGTT at 
discharge of an AMI meet all these criteria, with a target AMI-population, finding increased 
cardiovascular risk to a low cost by a test with no other harm other than discomfort by the 
glucose liquid in some cases. The criteria also comprise an accepted treatment for the patients 
with the newly detected disease in this case AGT. Apart from patients with type 2 diabetes, 
there are to date few studies demonstrating prognostic advantages with glucose lowering 
treatment in patients with IGT and AMI.248
The timing of the OGTT following an AMI is however of importance to consider. Wallander 
et al. demonstrated by repeating tests up to one year following the AMI that OGTT performed 
4-5 days after AMI is a reliable tool for assessment of the glucometabolic state with limited 
influence by stress in the acute setting.249 Knudsen et al. found OGTT to be a non-robust 
marker of glucometabolic disturbance when it was performed within the first two days 
after onset of symptoms suggesting that OGTT should be performed first day 4-5 to avoid 
the influence of stress.159 With the current shorter hospital stays this implicates a logistical 
concern where the most reasonable may be to analyse HbA1c and fasting glucose during 
hospital stay and to schedule the OGTT at the first follow-up two weeks after the index event. 
A great proportion of patients with glucose abnormalities would remain undetected using 
only fasting blood glucose or HbA1c as a screening procedure compared to OGTT.156,250-255 
In a report from EUROASPIRE IV OGTT had the greatest probability to identify undetected 
diabetes in stable CAD (detected 96%) compared to the combination of Hba1c and fasting 
plasma glucose (detected 81%).252 HbA1c has been emphasised to be more convenient than 
OGTT as it can be performed at any time of the day without fasting or stable situations and 
requires less resources.8 However there are limitations with HbA1c as it can be affected by 
other comorbidities and genetic factors.8 Taken together Study II supports the inclusion of 
OGTT as a screening tool, at least if prevalent CVD, not only for diagnosing diabetes but also 
for identifying individuals at high cardiovascular risk.
Adiponectin and leptin as biomarkers for identifying high risk patients
As discussed the combination of CVD and glucose abnormalities has serious prognostic 
consequences. Although this thesis cannot determine any direct causation dysregulated 
adipokines as adiponectin and leptin may be one mechanism of importance since dysglycaemia 
often co-exists with the metabolic syndrome including central obesity. In Study IV elevated 
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levels of adiponectin at discharge were associated with an increased risk of mortality the 
coming 12 years after an AMI.256 The risk tended to increase with time and cannot be explained 
by traditional risk factors such as age and obesity.256 These results were somewhat surprising 
considering that high rather than low levels of adiponectin predicted mortality, supporting 
the existence of an “adiponectin paradox”. The mechanism behind the increased risk of 
mortality associated with elevated levels of adiponectin after AMI is not fully understood 
and may seem contradictory, as adiponectin has been attributed anti-inflammatory and anti-
atherogenic properties. High levels of adiponectin during an acute coronary event may be 
indicative of a natural defence in a severe situation where adiponectin is upregulated in a 
compensatory manner. Patients that succumbed during the total follow-up time in Study 
IV but who survived until hospital discharge had increasing levels of adiponectin during 
hospitalisation. This might be a response to oxidative stress and inflammation from the acute 
event, and a warning sign for an inability to cellular adaptation to stress. It may be a possible 
reason why adiponectin at discharge (where adiponectin levels had raised) but not at day 2 
reflects total mortality. Patients with high adiponectin at discharge in Study IV were older, 
with a more frequent history of heart failure and a lower BMI implying that adiponectin can 
be indicative of other comorbidities or reflect cachexia and general catabolism. Antonopoulos 
et al. suggested that BNP and upstream pro inflammatory cytokines are key determinants of 
adiponectin by regulating the release of adiponectin from the adipose tissue.86 Adiponectin 
would then reflect the grade of systemic inflammation and is driven upward by circulating 
BNP levels.86 This cannot be further assessed in Study IV as NT-proBNP was not measured 
in the GAMI cohort, however only a minority (8%) of the patients had a previous diagnosed 
heart failure. 
Another important finding in Study IV is that leptin is associated with cardiovascular events 
up to seven years after the myocardial infarction. Plausible mechanisms could be the previous 
described association with increased levels of leptin and the atherosclerotic process including 
endothelial dysfunction, sympathetic activation, acute thrombosis and plaque rupture.100,101 
In the GAMI cohort with only slightly obese patients but with a high proportion of AGT, 
which is closely associated with leptin, it is likely that adipose tissue is redistributed to intra-
abdominal locations contributing to the increased risk of cardiovascular events.101 Contrary 
to adiponectin, levels of leptin did not predict total mortality. 
In summary, adiponectin captures patients with a high, long-term mortality risk (Study IV) 
while elevated levels of leptin and also a pathological OGTT (Study II) captures patients 
with increased risk for future cardiovascular events. Accordingly these markers may not 
necessarily reflect the same risk groups. Further research is needed to understand this 
discrepancy of these biomarkers, all easily available and measured in the acute setting of an 
acute coronary event, to further understand the underlying causes for the observed long-term 
risk. 
Mortality causes
In Study III the underlying cause of mortality in patients with established CAD was shown 
to have a similar pattern for those with and without diabetes although occurring at an 
earlier stage in those with known diabetes. Cardiovascular mortality was around 80% in the 
1990s in the DIGAMI cohort (Study I) and about 60% in those with diabetes mellitus in a 
population as the SCAAR cohort (Study III). Therefore it seems to have been a reduction in 
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causes of mortality from CVD probably explained by a longer life-expectancy for patients 
with diabetes resulting in other causes of mortality, such as endocrine and microvascular 
complications. This is in accordance with other reports, showing a decline in cardiovascular 
death related to diabetes with accompanying increase in deaths from other causes as cancer, 
endocrine and respiratory disorders.257, 258 However, one has to bear in mind that a greater 
proportion of the patients are followed until death in Study I compared to Study III and 
therefore proportion of mortality causes when all patients in Study III have been followed to 
mortality will be of interest to explore.  
Strengths and limitations of Studies I-IV
A major strength in Studies I, II and IV is the exceptional long follow-up time with no (Study 
I) or only one patient lost to follow-up (Studies II and IV) including almost all mortality 
in Study I. Study I is a randomised controlled trial allowing the investigation of a causal 
association between the intervention, an intensified insulin-based glycaemic control, and 
mortality. The relatively small sample size does, however, limit the statistical modelling 
where the outcome analyses of the predefined strata should mainly be regarded as indicative. 
Another limitation is that the type of glucose-lowering treatment was only known during 
the first year of follow-up. A cross-over may have taken place thereafter, with more insulin 
prescribed to patients in the control group by time. Moreover generalising of the results 
of Study I to present-day practice is difficult as the beneficial effect of glucose lowering 
on mortality may be less apparent with a modern secondary prevention strategy including 
statins and a greater proportion of angiotensin-converting enzyme inhibitors as previously 
discussed.
The limited number of patients in Studies II and IV provides an opportunity to get complete 
information on each individual and enables a careful ascertainment of cardiovascular events 
based on direct information from the patients, hospital records and national registries. 
However, the small sample size and limited number of events reduces the statistical power. 
Another limitation is that no information on treatment, possibly influencing prognosis, during 
follow-up is available. 
A major strength in Study III is the recruitment of a large and unselected cohort mirroring an 
everyday life setting. This provides more appropriate information on event types and rates 
after a PCI compared to trials performed on selected populations. However, as discussed, 
more detailed information on the extent and distribution of the CAD apart from in the affected 
arteries had been advantageous. Presently this important variable is not possible to adjust for 
as SYNTAX score or equivalent data are not included in SCAAR. A major limitation is the 
lack of diabetes related variables like type of diabetes, its duration and the actual glycaemic 
control which could further give insights on reasons for the high event rate in the insulin 
treated patients. Another limitation is the lack of information on long-term treatment after 
the PCI, like dual antiplatelet treatment and compliance to secondary prevention with statins 
and other drugs that may influence the prognosis.
Future directions
CVD is common in patients with diabetes and despite improved management longevity is 
still compromised compared with patients without diabetes. This refers both to diabetes in 
general and to those with prevalent cardiovascular disease. However today, in Sweden, the 
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underlying causes of mortality after myocardial infarction does not seem to differ between 
patients with or without diabetes mellitus although they occur at an earlier time point in 
the latter group. This illustrates the importance of preventing both development of diabetes, 
thereby reducing duration of overt diabetes and its adverse outcome including cardiovascular 
complications following an established event. Until recently focus has been on the impact of 
glucose lowering therapies. This approach had limited effects on cardiovascular mortality and 
morbidity unless the glycaemic control was very poorly controlled as in the DIGAMI study. 
In the future other preventive approaches than glucose control should be more prioritised. 
An attractive strategy could for instance be a multifactorial treatment targeting several 
components of the metabolic syndrome including an elevated state of inflammation. The 
ALECARDIO study was one such broad approach but was terminated due to lack of futility 
and drug related problems.259 Other novel therapies of interest are for instance PCSK9-
inhibitors and new pharmacological compounds reducing inflammation. Recent studies on 
PCSK9-inhibitors have shown promising reduction of LDL levels in diabetes.260 Ongoing 
trials will provide additional data if PCSK9 inhibition will have cardiovascular benefits 
not the least in the diabetes cohort. In patients with autoimmune diseases as rheumatoid 
arthritis methotrexate reduces the incidence of CVD.261 There are ongoing randomised 
studies to further explore if also patients with diabetes would benefit from anti-inflammatory 
treatment with methotrexate or IL-1 inhibitors. Bariatric surgery is another promising area 
with weight reduction and improvements of glycaemic control and dyslipidaemia in obese 
patients with dysregulated diabetes.262,263 In the 15 year follow-up of the non-randomised 
controlled Swedish Obesity Subjects study bariatric surgery was associated with a higher 
diabetes remission rate and less microvascular and macrovascular complications compared 
to controls.264 Bariatric surgery is currently recommended by ADA in individuals with BMI 
≥35 kg/m2 plus an obesity related comorbidity as diabetes as well as  by IDF in patients with 
BMI >30 kg/m2 not achieving treatment targets with optimal medical therapy.265,266 Larger 
randomised controlled trials with longer follow-up time are needed to further analyse the 
cardiovascular benefit in patients with type 2 diabetes. 
This thesis supports the inclusion of an OGTT as a screening tool after an AMI not only 
for diagnosing diabetes but also for identifying individuals at high cardiovascular risk. It 
strengthens the recommendation of OGTT as an important screening option in the ESC/
EASD guidelines.240 This is however not recommended in the most recent Swedish national 
cardiology guidelines.267 The question of whether an interventional program in patients with 
prediabetes and myocardial infarction would reduce cardiovascular complications is less 
well explored and future studies need to investigate this. 
Furthermore the substantially high event rate after a first PCI demonstrated in this thesis 
advocates a close follow-up to reduce the complication rate where cardiology units should 
consider a special follow-up program in patients with diabetes exceeding the usually eight 
weeks visit, preferably including a follow-up time during at least 12 months.
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CONCLUSIONS
1. Intensified insulin-based glycaemic control improves long-term survival after an acute 
myocardial infarction in patients with diabetes and substantially deranged glucose 
control. 
2. Newly detected glucose abnormalities by OGTT are common in patients with acute 
myocardial infarction and constitute an independent predictor of future cardiovascular 
mortality and morbidity during the coming decade. Patients with normal glucose 
tolerance have a very low event rate after an acute myocardial infarction. 
3. HbA1c is not an independent predictor of future cardiovascular events following a 
myocardial infarction either analysed as a continuous variable or when categorised 
according to recommended cut-off points for prediabetes or diabetes.
4. Patients with diabetes run a high risk of mortality and new cardiovascular events after a 
first PCI, such as myocardial infarction, heart failure and renewed PCI. Patients treated 
with insulin run a particularly high risk, including stent occlusions and restenosis. 
5. In patients with diabetes and established coronary artery disease, cardiovascular 
mortality is still the most common cause of death, with a proportion comparable to 
that in patients without diabetes.
6. In patients with acute myocardial infarction but without previously known diabetes, 
high levels of adiponectin constitute an independent predictor of long-term mortality, 
while high leptin levels are associated with future cardiovascular events.
Viveca Ritsinger
56
ACKNOWLEDGEMENTS
I have been fortunate and lucky to experience the best years of my life during my PhD studies 
at Karolinska Institutet. There are so many joyful memories, shared with all the wonderful 
people I have got to know along the way. They have meant a great deal to me and to whom I 
would like to express my sincere gratitude; 
First, I would like to express my deepest gratitude to my principal supervisor, Anna 
Norhammar, for your endless encouragement, hours of meaningful discussions and for 
being an outstanding role model! It has been a joy to work together and be inspired by your 
creative mind. I admire the way you mix successful research, clinical work and family time, 
always with a smile. You have really made these years a pleasure! It is a gift to be able to 
laugh together.
Lars Rydén, my co-supervisor, for believing in me and giving me the great honour of 
allowing me to be a part of your research group. Thank you for offering this PhD project and 
for your always instantaneous support and constructive feedback.
Klas Malmberg, my co-supervisor, for inspiration, meaningful discussions and an 
unforgettable time together at AHA 2013 in Dallas. 
Per Näsman, my co-supervisor, for agreeing to try to teach me SAS and having a great deal 
of patience, putting up with me and my preference for underscores and long variable names 
while learning statistics. 
 
Katarina Hedin, head of the Department of Research and Development Region Kronoberg, 
for believing in me and funding my PhD studies. Without you, this would never have been 
possible.
 
My co-authors in the studies for excellent collaboration and the privilege of working with you 
all; Bo Lagerqvist, Kerstin Brismar, Stefan Söderberg, Nawzad Saleh, Linda Mellbin, 
Eleni Tanoglidi, Åke Tenerz, Mattias Molin, Hans Wedel and Anton Mårtensson.
My wonderful colleagues at the Department of Research and Development, Region 
Kronoberg for meaningful discussions, always with a positive attitude and a true interest in 
what is occupying my time, making me long for my research periods and the meeting with an 
overnight stay at the end of the summer.
My wonderful colleagues at the Cardiology Research Unit at Karolinska University Hospital 
Solna, for always being warm, welcoming and caring and always throwing a great party 
every once in a while in different contexts.
Dorthe Geisler, David Ersgård and Eva Wallgren for helping me with the layout and 
putting my thesis together.
Agneta Andersson, my mentor, for offering me a residency at Ljungby lasarett and for 
believing that combining research and clinical work at a countryside hospital is indeed 
possible.
          Glucose abnormalities and cardiovascular disease
57
My wonderful colleagues at the Department of Medicine at Ljungby lasarett for your 
friendship, true support and putting up with my absence. For always enabling me to have a 
great time with you, making me love being a clinician and making me miss you when research 
keeps me away from you. To Peter Reinius, my supervisor, for guiding me in cardiology in 
an excellent and amusing way. To Jessica Kaminska, my wonderful roommate through the 
years, for keeping up with my desktop mess and sharing good and bad times together. To 
Ingrid Bodensten, for encouragement and always taking the time for a chat and a cup of tea 
beyond struggling with my absence on the schedule.
My friends, in particular Anna Ryberg, Johanna Wahlberg, Annie Sandell, Lina Hult 
and Katarina Gyllenberg, for long lasting friendship, inspiration and sharing both happy 
moments and hard times in life. You all show me what is really important in life.
My parents in law, Ingegerd and Christer, for welcoming me into your family, for supporting 
me, supplying me with outstanding home cooking and spoiling me with your time. 
My brother, John, with Anna, Elin and Ines, for sharing great memories together and being 
there during these years. John, I am proud to have been chosen as your first business mate in 
“John och Vivecas sjukvård” (even if Martina subsequently became your colleague in real 
life). I appreciate our close relationship, even at moments where there is little time to meet. 
My sister, Martina (madame secretary), with Erik and Juni, for offering the best support 
in everything I have done over the years. It is a blessing having you in my life and a luxury 
always being able to count on you day and night.
My grandma, Märta, wherever you are now, for your generosity and your infinite love. You 
are a big part of who I have become, inspiring me to set goals and strive to achieve them, 
convinced that nothing is impossible. I am grateful for all the days we had together and my 
heart will always be filled with memories of you.
My parents, Birgitta and Hans, for your endless love and encouragement. For always 
believing in me and making me try to do my best. For generosity, inspiration and so many 
joyful memories. For providing me with excellent service and a place to live while in 
Stockholm. For always letting your homes be open and welcoming. I love you! 
My husband, Martin, for love and support while walking through life together. You 
complement me and give me the opportunity constantly to learn new things. For truly 
sharing my passion for travel and for trying to share my interest in art and design. For always 
including me in your passion for wild boar hunting at midnight and for your generosity and 
positive approach to life.
Our children, Oscar and Victor, for being the light and meaning of my life. You are so smart 
and adorable. When you laugh, all memories of another sleepless night just go away. I am so 
grateful for being blessed with you in my life and words can never express how much I love 
you. I am so proud of you and of being your mother. I will always stand by your side.
This research program was supported by grants from the Department of Research and 
Development Region Kronoberg, the Family Kamprad Foundation, the Swedish Diabetes 
Association, the Swedish Heart-Lung Foundation and Västerås Hospital.
Viveca Ritsinger
58
1.  Dobson M. Experiments and observations on the urine in diabetes. Medical 
Observations and Inquiries 1776;5:298-316.
2.  Von Mehring J, Minkowski O. Diabetes mellitus nach pankreasexstirpation. Arch Exp 
Pathol Pharmakol 1890;26(5-6):371-87.
3.  Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in 
the treatment of diabetes mellitus: preliminary report. 1922. Cmaj 1991;145:1281-6.
4.  Diabetes mellitus. Report of a WHO expert committee. 1965.
5.  Diabetes mellitus. Report of a WHO study group. 1985.
6.  Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. 
Report of a WHO Consultation 1999.
7.  Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report 
of a WHO/IDF Consultation 2006.
8.  Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. 
Abbreviated Report of a WHO Consultation 2011.
9.  Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. 
Diabetes Care 2014;37(Suppl 1):S81-S90.
10.  Östlund I, Hanson U. Occurrence of gestational diabetes mellitus and the value of 
different screening indicators for the oral glucose tolerance test. Acta Obstet Gynecol 
Scand 2003;82(2):103-8.
11.  Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. 
WHO 2013.
12.  Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance 
of impaired fasting glucose versus impaired glucose tolerance. Importance of insulin 
secretion and resistance. Diab Care 2003;26:1333-7.
13.  Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-
607.
14.  Carnevale Schianca GP, Fra GP, Colli E, Bigliocca M, Mella R, Scaglia E, Bartoli E. 
Sex difference in lipid profile in relation to the progression of glucose abnormalities. 
J Diabetes 2012;4(1):95-101.
15.  Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the 
metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 
2006;95(3):136-47.
16.  Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev 
T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired 
glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose 
Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003; 26(3):868-74. 
17.  Neumann A, Norberg M, Schoffer O, Norström F, Johansson I, Klug SJ, Lindholm L. 
Risk equations for the development of worsened glucose status and type 2 diabetes 
mellitus in a Swedish intervention program. BMC Public Health 2013;13:1014.
18.  de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, 
Bouter LM, Heine RJ. Relation of impaired fasting and postload glucose with incident 
type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285(16):2109-13.
REFERENCES
          Glucose abnormalities and cardiovascular disease
59
19.  Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of 
diabetes in the new diagnostic category of impaired fasting glucose: a prospective 
analysis. Diabetes Care 1999;22(9):1490-3.
20.  Qiao Q, Lindstrom J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and 
treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. J 
Brit Diabetic Assoc 2003;20(12):1027-33.
21.  Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka 
P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, 
Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes 
mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N 
Engl J Med 2001;344(18):1343-50.
22.  Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, 
Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. 
Effects of diet and exercise in preventing NIDDM in people with impaired glucose 
tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
23.  Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai 
Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The 
long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing 
Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-9.
24.  Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker 
EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the 
incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 
2002; 346:393-403.
25.  Diabetes Prevention Program Research Group. Long-term effects of lifestyle 
intervention or metformin on diabetes development and microvascular complications 
over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet 
Diabetes Endocrinol 2015;(11):866-75.
26.  Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM 
Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-
NIDDM randomised trial. Lancet 2002;359(9323):2072-7.
27.  DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone 
Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan 
P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, 
Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with 
impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. 
Lancet 2006;368(9541):1096-105.
28.  Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly 
detected abnormal glucose tolerance: an important predictor of long-term outcome 
after myocardial infarction. Eur Heart J 2004;25:1990-7.
29.  Qiao Q, Pyörälä K, Pyörälä M, Nissinen A, Lindström J, Tilvis R, Tuomilehto J (for 
the Finnish DECODE sub-population). Two-hour glucose is a better risk predictor for 
incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur 
Heart J 2002; 23:1267-75.
30.  Stacey RB, Leaverton PE, Schocken DD, Peregoy JA, Bertoni AG. Prediabetes and 
the association with unrecognized myocardial infarction in the multi-ethnic study of 
atherosclerosis. Am Heart J 2015;170(5):923-8.
Viveca Ritsinger
60
31.  Laakso M, Kuusisto J. Understanding patient needs. Diabetology for cardiologists. 
Eur Heart J Supplements 2003;5(Suppl B):B5-B13.
32.  IDF Diabetes Atlas 7th edition. 2016. www.diabetesatlas.org
33.  Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. 
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 
2001;345(11):790-7.
34.  Mykkänen L, Laakso M, Uusitupa M, Pyörälä K. Prevalence of diabetes and impaired 
glucose tolerance in elderly subjects and their association with obesity and family 
history of diabetes. Diabetes Care 1990;13(11):1099-105.
35.  Global report on diabetes. WHO 2016.
36.  DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for 
NIDDM. Diabetes 1988;37(6):667-87.
37.  DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the 
treatment of type 2 diabetes mellitus. Diabetes 2009;58(4):773-95.
38.  Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, Baas AS, Paramsothy P, 
Giachelli CM, Corson MA, Raines EW. Free fatty acid impairment of nitric oxide 
production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc 
Biol 2005;25(5):989-94.
39.  Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444(7121):860-7.
40.  Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 
2005;307(5708):384-7.
41.  Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor 
necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 
1993;259(5091):87-91.
42.  Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-
alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its 
substrates. Biol Chem 1993;268(35):26055-8.
43.  Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning 
of the mouse obese gene and its human homologue. Nature 1994;372(6505):425-32.
44.  Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of 
obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. 
J Clin Endocrinol Metab 1998;83(3):847-50.
45.  Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, 
Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 
2001;409(6818):307-12.
46.  Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita 
S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression 
of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 
1996;2(7):800-3.
47.  Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, 
diabetes, and vascular diseases. Eur Heart J 2008;29(24):2959-71.
48.  Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and 
systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-
kappaB. Nat Med 2005;11(2):183-90. 
49.  Cissel DS, Beaven MA. Disruption of Raf-1/heat shock protein 90 complex and Raf 
signaling by dexamethasone in mast cells. J Biol Chem 2000;275(10):7066-70.
          Glucose abnormalities and cardiovascular disease
61
50.  De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad 
MJ, Velloso LA. Consumption of a fat-rich diet activates a proinflammatory 
response and induces insulin resistance in the hypothalamus. Endocrinology 2005 
Oct;146(10):4192-9.
51.  Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. 
Endocrinology 2004;145(11):4880-9.
52.  Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with 
leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 
2004;15(8):362-9.
53.  Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. 
Diabetes 1995;44(4):369-74.
54.  Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, 
Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and 
free fatty acid stimulate reactive oxygen species reduction through protein kinase 
C dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 
2000;49:1939-45.
55.  Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini 
G, De Mattia G, Santucci A. Insulin stimulates endothelin-1 secretion from human 
endothelial cells and modulates its circulation levels in vivo. J Clin Endocrinol Metab 
1995;80:829-35.
56.  De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial 
dysfunction in diabetes. Br J Pharmacol 2000;130(5):963-74.
57.  Laakso M. Epidemiology of diabetic dyslipidaemia. Diabetes Rev 1995;3:408-22
58.  Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: reducing 
the risk. Arterioscler Thromb Vasc Biol 1999;19:1819-24.
59.  Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in 
atherogenesis? J Clin Invest 2001;107:255-64.
60.  Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
61.  Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 
diabetes. Diabetes Care 2001;24:1476-85.
62.  Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery 
disease. N Engl J Med 2000;342:1792-1801.
63.  Cnop M, Havel PJ, Utzschneider KM. Relationship of adiponectin to body fat 
distribution, insulin sensitivity and plasma lipoproteins: evidence for independent 
roles of age and sex. Diabetologia 2003;46(4):459-69.
64.  Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, Maas 
D, Takahashi M, Kihara S, Tanaka S, Matsuzawa Y, Blangero J, Cohen D, Kissebah 
A. The genetic basis of plasma variation in adiponectin, a global endophenotype for 
obesity and the metabolic syndrome. J Clin Endocrinol Metab 2001;86:4321-5.
65.  Andreasson AN, Undén AL, Elofsson S, Brismar K. Leptin and adiponectin: 
distribution and associations with cardiovascular risk factors in men and women of 
the general population. Am J Hum Biol 2012;24(5):595-601.
66.  Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB. Plasma 
total and high molecular weight adiponectin levels and risk of coronary heart diasease 
in women. Atherosclerosis 2011;219:322-9.
Viveca Ritsinger
62
67.  Sattar N, Watt P, Cherry L, Ebrahim S, Davey Smith G, Lawlor DA. High molecular 
weight adiponectin is not associated with incident coronary heart disase in older women: 
a nested prospective case-control study. J Clin Endocrinol Metab 2008;93(5):1846-9. 
68.  Baessler A, Schlossbauer S, Stark K, Strack C, Riegger G, Schunkert H, Hengstenberg 
C, Fischer M. Adiponectin multimeric forms but not total adiponectin levels are 
associated with myocardial infarction in non-diabetes men. J Atheroscler Thromb 
2011;18(7):616-27.
69.  Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, 
Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono 
H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, 
Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted 
disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and 
metabolic actions. Nat Med 2007;13(3):332-9.
70.  Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, Fang Q, Liu DD, Torres JM, Jia W, 
Lechleiter JD, Liu F, Dong LQ. Adiponectin activates AMP-activated protein kinase 
in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/
calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 
2009;284(33):22426-35. 
71.  Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 
2005;26:439-51.
72.  Goldfine AB, Kahn CR. Linking the fat cell to insulin sensitivity. Lancet 
2003;362(9394):1431-2.
73.  Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and 
metabolic syndrome. Mol Cell Endocrinol 2010;314:1-16.
74.  Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, Kihara S, Funahashi T, 
Takata M, Temaru R, Sato A, Yamazaki K, Nakamura N, Kobayashi M. Adiponectin 
inhibits endothelial synthesis of interleukin-8. Circ Res 2005;97:1245-52.
75.  Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta 
K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, 
Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as 
a platelet-derived growth factor-BB-binding protein and regulates growth factor-
induced common postreceptor signal in vascular smooth muscle cell. Circulation 
2002;105(24):2893-8.
76.  Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto 
Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, 
Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The 
missing link of adipo-vascular axis. J Biol Chem 2002;277(40):37487-91.
77.  Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, 
Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita 
S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasmaprotein, adiponectin, 
suppresses lipid accumulation and class. A scavenger receptor expression in human 
monocyte-derived macrophages. Circulation 2001;103:1057-63.
78.  Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, Radha 
V. Association of low adiponectin levels with the metabolic syndrome--the Chennai 
Urban Rural Epidemiology Study (CURES-4). Metabolism 2005;54(4):476-81.
          Glucose abnormalities and cardiovascular disease
63
79.  Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating 
adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, 
and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes 
Care 2004;27(10):2450-7.
80.  Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, 
Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa 
K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. 
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 
diabetic patients. Arterioscler Thromb Vasc Biol 2000;20(6):1595-9.
81.  Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin 
levels and risk of myocardial infarction in men. JAMA 2004;291(14):1730-7.
82.  Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, 
Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y; Osaka 
CAD Study Group. Coronary artery disease. Association of hypoadiponectimemia 
with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
83.  Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, 
Marmur JD. Adiponectin is an independent predictor of all-cause mortality, cardiac 
mortality and myocardial infarction in patients presenting with chest pain. Eur Heart 
J 27(19):2300-9.
84.  Persson J, Folkersen L, Ekstrand J, Helleberg J, Gabrielsen A, Lundman P, Hedin U, 
Paulsson-Berne G. High plasma adiponectin concentration is associated with all-cause 
mortality in patients with carotid atherosclerosis. Atherosclerosis 2012;225(2):491-6.
85.  Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infarction: 
A paradox or a paradigm? Eur Heart J 2006;27:2266-8.
86.  Antonopoulos AS, Margaritis M, Coutinho P, Digby J, Patel R, Psarros C, Ntusi 
N, Karamitsos TD, Lee R, De Silva R, Petrou M, Sayeed R, Demosthenous M, 
Bakogiannis C, Wordsworth PB, Tousoulis D, Neubauer S, Channon KM, Antoniades 
C. Reciprocal effects of systemic inflammation and brain natriuretic peptide on 
adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. 
Arterioscler Thromb Vasc Biol 2014;34(9):2151-9.
87.  Szabó T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M, Jankowska 
EA, Rudovich N, Anker SD, Frystyk J, Flyvbjerg A, Pfeiffer AF, Doehner W. 
Plasma adiponectin in heart failure with and without cachexia: catabolic signal 
linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis 
2014;24(1):50-6.
88.  Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive 
clinical situation. J Ren Nutr 2011;21(1):82-6.
89.  Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. Hydroxylation and glycosylation of the 
four conserved lysine residues in the collagenous domain of adiponectin. Potential role 
in the modulation of its insulin-sensitizing activity. J Biol Chem 2002;277(22):19521-9.
90.  Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic 
strategy. Atherosclerosis 2014;233(2):721-8.
91.  Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004;81:223-41.
92.  Sinha MK, Caro JF. Clinical aspects of leptin. Vitam Horm 1998;54:1-30.
Viveca Ritsinger
64
93.  Zhao SP, Wu ZH. Atorvastatin reduces serum leptin concentration in 
hypercholesterolemic rabbits. Clin Chim Acta 2005;360:133-40.
94.  Törüner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Aktürk M, Karakoç A, 
Ayvaz G, Arslan M. Effects of PPARgamma and PPARalpha agonists on serum leptin 
levels in diet-induced obese rats. Horm Metab Res 2004;36:226-30.
95.  De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann 
LG, Staels B, Briggs MR, Auwerx J. Thiazolidinediones repress ob gene expression 
in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin 
Invest 1996;98:1004-9.
96.  Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. 
Nature 1998;395:763-70.
97.  de Gusmao Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. 
Curr Opin Nephrol Hypertens 2004;13:215-23.
98.  Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 
2005;16:307-13.
99.  Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions 
and interactions. Int J Obes Relat Metab Disord 2002;26:1407-33.
100.  Sweeney G. Cardiovascular effects of leptin. Nat Rev Cardiol 2010;7:22-9.
101.  Bełtowski J. Leptin and the regulation of endothelial function in physiological and 
pathological conditions. Clin Exp Pharmacol Physiol 2012;39(2):168-78.
102.  Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, 
Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin 
concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
103.  Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: 
a new concept in leptin physiology with cardiovascular implications. J Hypertens 
2002;20:1245-50.
104.  Ren J. Leptin and hyperleptinemia- from friend to foe for cardiovascular function. J 
Endocrinol 2004;181:1-10.
105.  Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina 
JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss 
in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 
1999;282(16):1568-75.
106.  Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 
2004;53(1):152-8.
107.  Opie L. Metabolic management of acute myocardial infarction comes to the fore and 
extends beyond control of hyperglycemia. Circulation 2008;117(17):2172-7.
108.  Leclercq I, da Silva Morais A, Schroyen B, van Hul N, Geerts A. Insulin resistance 
in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 
2007;47(1):142-56.
109.  Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and 
paracrine organ. Int J Obes 1998;22:1145-58.
110.  Wauters M, Considine RV,Van Gaal LF. Human leptin: from an adipocyte hormone to 
an endocrine mediator. Eur J Endocrinol 2000;143:293-311.
111.  Sivan E, Whittaker P, Sinha D, Homko CJ, Lin M, Reece EA, Boden G. Leptin in 
          Glucose abnormalities and cardiovascular disease
65
human pregnancy: the relationship with gestational hormones. Am J Obstet Gynecol 
1998;179(5):1128-32. 
112.  Kristensen K, Pedersen SB, Richelsen B. Regulation of leptin by steroid hormones in 
rat adipose tissue. Biochem Biophys Res Commun 1999;259(3):624-30.
113.  Nyström F, Ekman B, Osterlund M, Lindström T, Ohman KP, Arnqvist HJ. Serum 
leptin concentrations in a normal population and in GH deficiency: negative 
correlation with testosterone in men and effects of GH treatment. Clin Endocrinol 
(Oxf) 1997;47(2):191-8.
114.  Wauters M, Mertens I, Considine R, De Leeuw I, Van Gaal L. Are leptin levels 
dependent on body fat distribution in obese men and women? Eat Weight Disord 
1998;3:124-30.
115.  Brydon L, O’Donnell K, Wright CE, Wawrzyniak AJ, Wardle J, Steptoe A. 2008. 
Circulating leptin and stress-induced cardiovascular activity in humans. Obesity 
(Silver Spring) 2008;16(12):2642-7. 
116.  Brydon L, Wright CE, O’Donnell K, Zachary I, Wardle J, Steptoe A. Stress-induced 
cytokine responses and central adiposity in young women. Int J Obes (Lond) 
2008;32:443-50.
117.  Söderberg S, Stegmayr B, Stenlund H, Sjöström LG, Agren A, Johansson L, Weinehall 
L, Olsson T. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 
2004;256:128-36. 
118.  Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin 
and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 
2004;44:1819-24.
119.  Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. 
Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary 
prevention study (WOSCOPS). Circulation 2001;104:3052-6. 
120.  Söderberg S, Ahrén B, Jansson JH, Johnson O, Hallmans G, Asplund K, Olsson 
T. Leptin is associated with increased risk of myocardial infarction. J Intern Med 
1999;246:409-18.
121.  Chai SB, Sun F, Nie XL, Wang J. Leptin and coronary heart disease: a systematic 
review and meta-analysis. Atherosclerosis 2014;233(1):3-10.
122.  Couillard C, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, 
Lupien PJ, Després JP. Leptinemia is not a risk factor for ischemic heart disease 
in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 
1998;21(5):782-6.
123.  Lawlor DA, Smith GD, Kelly A, Sattar N, Ebrahim S. Leptin and coronary heart 
disease risk: prospective case control study of British women. Obesity (Silver Spring) 
2007;15(7):1694-701.
124.  Vavruch C, Länne T, Fredrikson M, Lindström T, Östgren CJ, Nystrom FH. Serum 
leptin levels are independently related to the incidence of ischemic heart disease in a 
prospective study of patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:62.
125.  Brennan AM, Li TY, Kelesidis I, Gavrila A, Hu FB, Mantzoros CS. Circulating leptin 
levels are not associated with cardiovascular morbidity and mortality in women with 
diabetes: a prospective cohort study. Diabetologia 2007;50(6):1178-85.
Viveca Ritsinger
66
126.  Antonopoulos AS, Antoniades C, Tousoulis D. Unravelling the “adipokine paradox”: 
When the classic proatherogenic adipokine leptin is deemed the beneficial one. Int J 
Cardiol 2015;197:125-7.
127.  The effect of intensive treatment of diabetes on the development and progression of 
long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control 
and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86.
128.  UK Prospective Diabetes Study Group. Intensive blood glucose control 
with sulphonylureas or insulin compared with conventional treatment and 
risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 
1998;352(9131):837-53.
129.  The Swedish renal registry annual report 2015. www.medscinet.net/snr.
130.  Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser 
RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a 
statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-62.
131. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, 
Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet 2004;364(9438):937-52.
132.  Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary 
heart disease in women compared with men: a systematic review and meta-analysis of 
64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 
2014;57(8):1542-51. 
133.  Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart 
disease risk factors in prediabetic women than in prediabetic men. Diabetologia 
1997;40:711-17.
134.  Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex 
differences in endothelial function markers before conversion to pre-diabetes: does 
the clock start ticking earlier among women? TheWestern New York Study. Diabetes 
Care 2007;30:354-9.
135.  UK Prospective Diabetes Study IV. Characteristics of newly presenting type 2 diabetic 
patients: male preponderance and obesity at different ages. Multi-center Study. Diabet 
Med 1988;5:154-9.
136.  Paul S, Thomas G, Majeed A, Khunti K, Klein K. Women develop type 2 diabetes at 
a higher body mass index than men. Diabetologia 2012;55:1556-7.
137.  Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W. Sex disparities 
in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes 
Care 2008;31:1389-91.
138.  Franzini L, Ardigò D, Cavalot F, Miccoli R, Rivellese AA, Trovati M, Zavaroni I, 
Vaccaro O. Women show worse control of type 2 diabetes and cardiovascular disease 
risk factors than men: results from the MIND.IT Study Group of the Italian Society of 
Diabetology. Nutr Metab Cardiovasc Dis 23(3):235-41.
139.  Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale 
CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence 
of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes 
Endocrinol 2015;3(2):105-13. 
140.  Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of 
          Glucose abnormalities and cardiovascular disease
67
intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89.
141.  Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin 
L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin 
treatment in diabetic patients with acute myocardial infarction (DIGAMI study): 
effects on mortality at 1 year. J Am Coll Cardiol 1995;26(1):57-65.
142.  Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting 
plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. 
Circulation 2000;101(17):2047-52.
143.  Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for 
mortality risk? Diabetes Care 1999;22(5):696-9.
144.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. The Emerging 
Risk Factors Collaboration. N Engl J Med 2011;364:829-41.
145.  Gottlieb MS. The natural history of diabetics: factors presented at time of diagnosis 
which may be predictive of length of survival. J Chron. Dis 1974;27:435-45.
146.  Public health report 2014. www.folkhalsomyndigheten.se
147.  Levine SA. Coronary thrombosis: its various clinical features. Medicine 1929;8:245-
418.
148.  Opie LH, Stubb WA. Carbohydrate metabolism in cardiovascular disease. Clin 
Endocrinol Metab 1976;3:703-29.
149.  Ellenberg M, Osserman KE, Pollack H. Hyperglycemia in coronary thrombosis. 
Diabetes 1952;1:16-21.
150.  Taylor SH, Saxton C, Majid PA, Dykes JR, Ghosh P, Stoker JB. Insulin secretion 
following myocardial infarction with particular respect to the pathogenesis of 
cardiogenic shock. Lancet 1969;2(7635):1373-8.
151.  Wahlberg F. Intravenous glucose tolerance in myocardial infarction, angina pectoris 
and intermittent claudication. Acta Med Scand Suppl 1966;453:1-93.
152.  Paasikivi J. Long-term tolbutamide treatment after myocardial infarction. Acta Med 
Scand Suppl 1970;507:1-82.
153.  University Group Diabetes Program. A study of the effects of hypoglycemic agents 
on vascular complication in patients with adult-onset diabetes: II. Mortality results. 
Diabetes 1970;19:Suppl:789-830.
154.  WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ 
Tech Rep Ser 1980;646:1-80.
155. EUROASPIRE I and II Group; European Action on Secondary Prevention by 
Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a 
comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357(9261):995-
1001.
156.  Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. 
Glucose metabolism in patients with acute myocardial infarction and no previous 
diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359(9324):2140-4.
157.  Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-
Soler J, Ohrvik J; Euro Heart Survey Investigators. The prevalence of abnormal 
glucose regulation in patients with coronary artery disease across Europe. The Euro 
Heart Survey on diabetes and the heart. Eur Heart J 2004;25(21):1880-90.
158.  Hu DY, Pan CY, Yu JM. The relationship between coronary artery disease and abnormal 
glucose regulation in China: the China Heart Survey. Eur Heart J 2006;27:2573-9.
Viveca Ritsinger
68
159.  Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, 
Andersen GO. Abnormal glucose regulation in patients with acute ST- elevation 
myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol 2009;8:6. 
160.  Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly 
detected abnormal glucose tolerance: an important predictor of long-term outcome 
after myocardial infarction. Eur Heart J 2004;25(22):1990-7.
161.  Lenzen M, Rydén L, Öhrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, 
Simoons ML; Euro Heart Survey Investigators. Diabetes known or newly detected, 
but not impaired glucose regulation, has a negative influence on 1-year outcome in 
patients with coronary artery disease: a report from the Euro Heart Survey on diabetes 
and the heart. Eur Heart J 2006;27(24):2969-74.
162.  Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, Morioka S, Kihara 
Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in 
patients with acute myocardial infarction. Circ J 2007;71(6):834-41.
163.  George A, Bhatia RT, Buchanan GL, Whiteside A, Moisey RS, Beer SF, Chattopadhyay 
S, Sathyapalan T, John J. Impaired Glucose Tolerance or Newly Diagnosed Diabetes 
Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial 
Infarction: An Observational Study. PLoS One 2015;10(11):e0142045. 
164.  Sodi-Pallares D, Bisteni A, Medrano G. The polarizing treatment of acute myocardial 
infarction. Dis Chest 1963;43:424-32.
165.  Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D’Agostino RB, 
Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude 
DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, 
Walter GP, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE. 
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients 
with suspected acute coronary syndromes: the IMMEDIATE randomized controlled 
trial. JAMA 2012;307(18):1925-33.
166.  van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, 
Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in 
critically ill patients. N Engl J Med 2001;345(19):1359-67.
167.  Grossman AN, Opie LH, Beshansky JR, Ingwall JS, Rackley CE, Selker HP. Glucose-
insulin-potassium revived: current status in acute coronary syndromes and the energy-
depleted heart. Circulation 2013 Mar 5;127(9):1040-8.
168.  NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster 
D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, 
Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, 
Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill 
patients. N Engl J Med 2009 Mar;360(13):1283-97. 
169.  ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, 
Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, 
Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, 
de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in 
patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72. 
170.  Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller 
ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-
Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of 
          Glucose abnormalities and cardiovascular disease
69
intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59. 
171.  Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, 
Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen 
C, Waldenström A; DIGAMI 2 Investigators. Intense metabolic control by means of 
insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 
2): effects on mortality and morbidity. Eur Heart J 2005;26(7):650-61.
172.  Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion 
in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for 
myocardial infarction. Diabetes Care 2006;29(4):765-70.
173.  Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, 
Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, 
Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular 
complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
174.  Effect of intensive blood-glucose control with metformin on complications in 
overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes 
Study (UKPDS) Group. Lancet 1998;352(9131):854-65.
175.  Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE 
trials. N Engl J Med 2008;358(24):2630-3.
176.  Riddle MC. Glycemic control and cardiovascular mortality. Curr Opin Endocrinol 
Diabetes Obes 2011;18(2):104-9. 
177.  Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus 
M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG 
OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality 
in Type 2 Diabetes. N Engl J Med 2015;373(22):2117-28. 
178.  Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, 
Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, 
Bergenstal RM, Buse JB; LEADER Steering Committee on behalf of the LEADER 
Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N 
Engl J Med 2016 Jun 13. Epub ahead of print.
179.  Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, 
Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, 
Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in 
Patients with Type 2 Diabetes. N Engl J Med 2016 Sep 15. Epub ahead of print.
180.  The U.S. Food and Drug Administration. www.fda.gov
181.  Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular 
events. Diabetes Care 2010;33(6):1389-94. 
182.  Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, Heller SR. 
Altered ventricular repolarization during hypoglycaemia in patients with diabetes. 
Diabet Med 1997;14(8):648-54.
183.  Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S, Hanefeld M. 
Relationship between hypoglycemic episodes and ventricular arrhythmias in patients 
with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent 
arrhythmias. Diabetes Care 2014;37(2):516-20. 
184.  Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating 
factor? Diabetes Metab Res Rev 2008;24(5):353-63. 
Viveca Ritsinger
70
185.  Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, 
Gozashti MH, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-
induced hypoglycemic stress in healthy subjects. Metabolism 2009;58(4):443-8. 
186.  Ceriello A, Novials A, Ortega E, La Sala L, Pujadas G, Testa R, Bonfigli AR, 
Esposito K, Giugliano D. Evidence that hyperglycemia after recovery from 
hypoglycemia worsens endothelial function and increases oxidative stress and 
inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes 
2012;61(11):2993-7. 
187.  Ryan TJ. The coronary angiogram and its seminal contributions to cardiovascular 
medicine over five decades. Circulation 2002;106(6):752-6.
188.  Captur G. Memento for René Favaloro. Tex Heart Inst J 2004;31(1):47-60.
189.  Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 
1978;1(8058):263.
190.  Puel J, Joffre F, Rousseau H, Guermonprez JL, Lancelin B, Morice MC, Valeix B, 
Imbert C, Bounhoure JP. Self-expanding coronary endoprosthesis in the prevention 
of restenosis following transluminal angioplasty. Preliminary clinical study. Arch Mal 
Coeur Vaiss 1987;80(8):1311-2.
191.  Meier B. Stenting, quite a legacy of Charles, Charles, and Arthur. Cathet Cardiovasc 
Diagn 1998;45:233-4.
192.  King SB 3rd, Meier B. Interventional treatment of coronary heart disease and 
peripheral vascular disease. Circulation 2000;102(20 Suppl 4):IV81-6.
193.  Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O’Keefe J, Overlie P, 
Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-
Ochocki S, O’Neill WW, and the Primary Angioplasty in Myocardial Infarction Study 
Group. A comparison of immediate angioplasty with thrombolytic therapy for acute 
myocardial infarction. N Engl J Med 1993;328(10):673-9.
194.  Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A 
comparison of immediate coronary angioplasty with intravenous streptokinase in 
acute myocardial infarction. N Engl J Med 1993;328(10):680-4.
195.  FRISC Investigators and Committee Members. Invasive compared with non-invasive 
treatment in unstable coronary-artery disease: FRISC II prospective randomised 
multicentre study. Lancet 1999;354:708-15.
196.  Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E, Wallentin L; Fast 
Revascularisation during InStability in Coronary artery disease (FRISC-II) 
Investigators. 5-year outcomes in the FRISC-II randomised trial of an invasive versus 
a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up 
study. Lancet 2006;368(9540):998-1004.
197.  Lagerqvist B, Diderholm E, Lindahl B, Husted S, Kontny F, Ståhle E, Swahn E, Venge 
P, Siegbahn A, Wallentin L. FRISC score for selection of patients for an early invasive 
treatment strategy in unstable coronary artery disease. Heart 2005;91(8):1047-52.
198.  Quigley PJ, Hlatky MA, Hinohara T, Rendall DS, Perez JA, Phillips HR, Califf RM, 
Stack RS. Repeat percutaneous transluminal coronary angioplasty and predictors of 
recurrent restenosis. Am J Cardiol 1989;63:409-13.
199.  Weintraub WS, Kosinski AS, Brown CL, King SB. Can restenosis after coronary 
angioplasty be predicted from clinical variables? J Am Coll Cardiol 1993;21:6-14.
          Glucose abnormalities and cardiovascular disease
71
200.  Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty 
in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous 
Transluminal Coronary Angioplasty Registry. Circulation 1996;94(8):1818-25
201.  Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri 
L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, 
Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, 
Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison 
of coronary-stent placement and balloon angioplasty in the treatment of coronary 
artery disease. N Engl J Med 1994;331(8):496-501.
202.  James SK, Stenestrand U, Lindbäck J, Carlsson J, Scherstén F, Nilsson T, Wallentin 
L, Lagerqvist B; SCAAR Study Group. Long-term safety and efficacy of drug-eluting 
versus bare-metal stents in Sweden. N Engl J Med 2009;360(19):1933-45. 
203.  Stenestrand U, James SK, Lindbäck J, Fröbert O, Carlsson J, Scherstén F, Nilsson 
T, Lagerqvist B; SCAAR/SWEDEHEART study group. Safety and efficacy of drug-
eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in 
the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 
2010;31(2):177-86.
204.  Norhammar A, Lindbäck J, Rydén L, Wallentin L, Stenestrand U; Register of 
Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-
HIA). Improved but still high short- and longterm mortality rates after myocardial 
infarction in patients with diabetes mellitus: a time-trend report from the Swedish 
Register of Information and Knowledge about Swedish Heart Intensive Care 
Admission. Heart 2007;93:1577-83. 
205.  The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. 
Comparison of coronary bypass surgery with angioplasty in patients with multivessel 
disease. N Engl J Med 1996;335:217-25. 
206.  Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle 
E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, 
Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus 
coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 
2009;360(10):961-72. 
207.  Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, 
Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky 
A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse 
J, Hueb W, Smith CR, Muratov V, Bansilal S, King S III, Bertrand M, Fuster V; 
FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients 
with diabetes. N Engl J Med 2012;367:2375-84.
208.  National Diabetes Data Group. Classifications and diagnosis of diabetes mellitus and 
other categories of glucose intolerance. Diabetes 1979;28(12):1039-57.
209.  Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint 
International Society and Federation of Cardiology/World Health Organization task 
force on standardization of clinical nomenclature. Circulation 1979;59(3):607-9.
210.  Myocardial infarction redefined - A consensus document of The Joint European Society 
of Cardiology/American College of Cardiology Committee for the Redefinition of 
Myocardial Infarction. Eur Heart J 2000;21:1502-16.
Viveca Ritsinger
72
211.  Walker AE, Robins M, Weinfeld FD. The national survey of stroke: clinical findings. 
Stroke 1981;12(Suppl F, pt2):I13-44.
212.  Jeppsson JO1, Jerntorp P, Almër LO, Persson R, Ekberg G, Sundkvist G. Capillary 
blood on filter paper for determination of HbA1c by ion exchange chromatography. 
Diabetes Care 1996;19(2):142-5.
213.  Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John 
WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont 
L, Umemoto M, Wiedmeyer HM; IFCC Working Group on HbA1c Standardization. 
IFCC reference system for measurement of hemoglobin A1c in human blood and the 
national standardization schemes in the United States, Japan and Sweden: a method-
comparison study. Clin Chem 2004;50:166-74.
214.  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
215.  Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner 
RC, Holman RR. Association of glycaemia with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 
2000;321(7258):405-12.
216.  Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, 
Turner RC, Holman RR. Association of systolic blood pressure with macrovascular 
and microvascular complications of type 2 diabetes (UKPDS 36): prospective 
observational study. BMJ 2000;321(7258):412-9.
217.  Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes 
Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary 
heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101(6):671-9.
218.  Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial 
intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 
2003;348(5):383-93.
219.  Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for 
long-term prognosis. Diabetes 2004;53 Suppl 3:S39-47.
220.  Ritsinger V, Malmberg K, Mårtensson A, Rydén L, Wedel H, Norhammar A. 
Intensified insulin-based glycaemic control after myocardial infarction improves 
long-term survival. Twenty-year follow-up of the Diabetes Mellitus Insulin Glucose 
Infusion in Acute Myocardial Infarction (DIGAMI) study. Lancet Diabetes Endocrinol 
2014;2(8):627-33.
221.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive 
diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl 
J Med 2005;353(25):2643-53.
222.  Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of 
Scotland Coronary Prevention Study Group. Long-term follow-up of theWest of 
Scotland Coronary Prevention Study. N Engl J Med 2007;357(15):1477-86.
223.  HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on 
cardiovascular events and on diabetes. Results of the HOPE study extension. 
Circulation 2005;112:1339-46.
          Glucose abnormalities and cardiovascular disease
73
224.  Marre M. The legacy effect in type 2 diabetes: fact or fiction? Medicographia 
2013;35:53-60. 
225.  Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, 
Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial 
superoxide production blocks three pathways of hyperglycaemic damage. Nature 
2000;404(6779):787-90.
226.  Paneni F, Costantino S, Castello L, Battista R, Capretti G, Chiandotto S, D’Amario 
D, Scavone G, Villano A, Rustighi A, Crea F, Pitocco D, Lanza G, Volpe M, Del Sal 
G, Lüscher TF, Cosentino F. Targeting prolyl-isomerase Pin1 prevents mitochondrial 
oxidative stress and vascular dysfunction: insights in patients with diabetes. Eur Heart 
J 2015;36(13):817-28.
227.  Ceriello A, Ihnat MA, Thorpe JE. The “metabolic memory”: is more than just tight 
glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 
2009;94(2):410-5.
228.  Costantino S, Paneni F, Lüscher TF, Cosentino F. MicroRNA profiling unveils 
hyperglycaemic memory in the diabetic heart. Eur Heart J 2016;37(6):572-6.
229.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: 
the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
230.  Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, Senior P; 
ACCORD Investigators. The impact of frequent and unrecognized hypoglycemia on 
mortality in the ACCORD study. Diabetes Care 2012;35(2):409-14.
231.  Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, 
Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, 
Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between 
symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective 
epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909. 
232.  NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster 
D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, 
Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, 
Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill 
patients. N Engl J Med 2009;360(13):1283-97.
233.  ORIGIN Trial Investigators, Mellbin LG, Rydén L, Riddle MC, Probstfield J, 
Rosenstock J, Díaz R, Yusuf S, Gerstein HC. Does hypoglycaemia increase the risk of 
cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34(40):3137-
44.
234.  Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya 
T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE 
Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N 
Engl J Med 2010;363(15):1410-8.
235.  Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 
2 Diabetes: Is the Picture Clear? Diabetes Care 2016;39(Suppl 2):S187-95.
236.  Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in 
type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad 
Sci 2013;1281:36-50.
Viveca Ritsinger
74
237.  Swedeheart Annual report 2015. www.ucr.uu.se/swedeheart
238.  Ritsinger V, Saleh N, Lagerqvist B, Norhammar A. High event rate after a first 
percutaneous coronary intervention (PCI) in patients with diabetes. Results from the 
Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Circ Cardiovasc 
Interv 2015;8(6):e002328.
239.  McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular 
outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 
2014;2(10):843-51. 
240.  Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned 
J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, 
Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano 
JL; ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, 
Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari 
R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, 
Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, 
Torbicki A, Wijns W, Windecker S; Document Reviewers, De Backer G, Sirnes PA, 
Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, 
Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus 
JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, 
Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, 
Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, 
pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: 
the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European 
Society of Cardiology (ESC) and developed in collaboration with the European 
Association for the Study of Diabetes (EASD). Eur Heart J 2013;34(39):3035-87.
241.  Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, Abizaid A, 
Buller CE, Devlin G, Rodriguez AE, Lansky AJ, Siami FS, Domanski M, Fuster V; 
FREEDOM Investigators. Long-term outcome of PCI versus CABG in insulin and 
non-insulin-treated diabetic patients: results from the FREEDOM trial. J Am Coll 
Cardiol 2014;64(12):1189-97.
242.  Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield 
J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S; ORIGIN Trial Investigators. 
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 
2012;367:319-28.
243.  Ritsinger V, Tanoglidi E, Malmberg K, Näsman P, Rydén L, Tenerz Å, Norhammar A. 
Sustained prognostic implications of newly detected glucose abnormalities in patients 
with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in 
Patients with Acute Myocardial Infarction cohort. Diab Vasc Dis Res 2015;12(1):23-32.
244.  Kuhl J, Jörneskog G, Wemminger M, Bengtsson M, Lundman P, Kalani M. Long-
term clinical outcome in patients with acute coronary syndrome and dysglycaemia. 
Cardiovasc Diabetol 2015;14:120.
245.  George A, Bhatia RT, Buchanan GL, Whiteside A, Moisey RS, Beer SF, Chattopadhyay 
S, Sathyapalan T, John J. Impaired Glucose Tolerance or Newly Diagnosed Diabetes 
Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial 
Infarction: An Observational Study. PLoS One 2015;10(11):e0142045.
246.  Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: 
WHO 1968.
          Glucose abnormalities and cardiovascular disease
75
247.  Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner 
in the genomic age: a review of screening criteria over the past 40 years: Bulletin of 
the World Health Organization 2008;86(4):241-320.
248.  Yun P, Du AM, Chen XJ, Liu JC, Xiao H. Effect of Acarbose on Long-Term Prognosis 
in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose 
Tolerance. J Diabetes Res 2016;1602083.
249.  Wallander M, Malmberg K, Norhammar A, Rydén L, Tenerz A. Oral glucose tolerance 
test: a reliable tool for early detection of glucose abnormalities in patients with acute 
myocardial infarction in clinical practice: a report on repeated oral glucose tolerance 
tests from the GAMI study. Diabetes Care 2008;31(1):36-8.
250.  Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-
Soler J, Ohrvik J; Euro Heart Survey Investigators. The prevalence of abnormal 
glucose regulation in patients with coronary artery disease across Europe. The Euro 
Heart Survey on diabetes and the heart. Eur Heart J 2004;25(21):1880-90.
251.  Bartnik M, Rydén L, Malmberg K, Ohrvik J, Pyörälä K, Standl E, Ferrari R, Simoons 
M, Soler-Soler J; Euro Heart Survey Investigators. Oral glucose tolerance test is 
needed for appropriate classification of glucose regulation in patients with coronary 
artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 
2007;93(1):72-7.
252.  Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Sundvall J, Tuomilehto 
J, Wood D, Rydén L; EUROASPIRE IV Investigators. Screening for dysglycaemia 
in patients with coronary artery disease as reflected by fasting glucose, oral glucose 
tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the 
European Society of Cardiology. Eur Heart J 2015;36(19):1171-7.
253.  Christensen DL, Witte DR, Kaduka L, Jørgensen ME, Borch-Johnsen K, Mohan 
V, Shaw JE, Tabák AG, Vistisen D. Moving to an A1C-based diagnosis of diabetes 
has a different impact on prevalence in different ethnic groups. Diabetes Care 
2010;33(3):580-2.
254.  de la Hera JM, García-Ruiz JM, Martínez-Camblor P, Martín M, Tellería AL, Corros 
C, Torres F, Fernández-Cimadevilla OC, Alvarez-Pichel I, Capín E, Avanzas P, 
Delgado E. Real incidence of diabetes mellitus in a coronary disease population. Am 
J Cardiol 2013;111(3):333-8. 
255.  Pajunen P, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-
Kiukaanniemi S, Uusitupa M, Tuomilehto J, Lindström J. HbA(1c) in diagnosing 
and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes 
Prevention Study. Diabet Med 2011;28(1):36-42.
256.  Ritsinger V, Brismar K, Malmberg K, Mellbin L, Näsman P, Rydén L, Söderberg S, 
Tenerz Å, Norhammar A. Elevated levels of adipokines predict outcome after acute 
myocardial infarction - a long-term follow up of the GAMI cohort. Diab Vasc Dis Res 
2017; In press.
257.  Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano DJ. Mortality trends 
among people with type 1 and type 2 diabetes in  Australia: 1997–2010. Diabetes 
Care 2014;37:2579-86.
258.  Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet 
Diabetes Endocrinol 2016;4(6):537-47.
Viveca Ritsinger
76
259.  Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, 
Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee 
DE; AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after 
acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio 
randomized clinical trial. JAMA 2014;311(15):1515-25.
260.  Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman 
SM, Raal FJ. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 
145) in patients with type 2 diabetes: a meta-analysis of individual patient data. 
Lancet Diabetes Endocrinol 2016;4(5):403-10.
261.  Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards 
CJ. The effect of methotrexate on cardiovascular disease in patients with rheumatoid 
arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49(2):295-307.
262.  Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, 
Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR; STAMPEDE Investigators. 
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N 
Engl J Med 2014;370(21):2002-13.
263.  Madsbad S, Holst JJ. Guidelines: Surgical or medical therapy for patients with obesity 
and T2DM? Nat Rev Endocrinol 2016;12(9):500-2
264.  Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, 
Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, 
Wedel H, Svensson PA, Sjöholm K, Carlsson LM. Association of bariatric surgery 
with long-term remission of type 2 diabetes and with microvascular and macrovascular 
complications. JAMA 2014;311(22):2297-304.
265.  Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, 
Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, 
Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK; American Heart Association 
Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council 
on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on 
Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes 
Research; American Diabetes Association. Update on Prevention of Cardiovascular 
Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A 
Scientific Statement From the American Heart Association and the American Diabetes 
Association. Diabetes Care 2015;38(9):1777-803.
266.  Dixon JB, Zimmet P, Alberti KG, Rubino F; International Diabetes Federation 
Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for 
obese type 2 diabetes. Diabet Med 2011;28:628-42.
267.  National guidelines for cardiac care 2015. www.socialstyrelsen.se
